Day: August 10, 2026

A Practical Framework for Clinical Governance, Staffing, Safety, Documentation, Quality Improvement, and Survey Readiness

Accreditation provides an independent assessment of whether a hyperbaric oxygen therapy program has the systems needed to deliver safe, consistent, and clinically appropriate care. It evaluates far more than the condition of the hyperbaric chambers. The review extends to medical leadership, staff qualifications, patient selection, treatment documentation, fire prevention, equipment maintenance, emergency readiness, and quality improvement.

In the United States, the Undersea and Hyperbaric Medical Society, or UHMS, operates a voluntary specialty accreditation program for clinical hyperbaric facilities. Its evaluation examines the adequacy of the facility, equipment, personnel, training, clinical care, and safety systems. The current UHMS Clinical Hyperbaric Facility Accreditation Manual is the Fourth Edition. (UHMS)

Accreditation should not be treated as a certificate obtained shortly before a survey. The requirements are intended to describe how the program functions every day, including when equipment fails, staffing changes, a patient deteriorates, or a safety concern interrupts treatment.

Accreditation, Licensure, and Regulatory Compliance Are Different

Hyperbaric accreditation is not the same as state licensure, hospital accreditation, Medicare participation, or FDA device clearance.

A facility may be subject to several overlapping requirements:

• State healthcare facility and professional licensing rules
• Local building, electrical, medical gas, and fire codes
• Hospital or ambulatory facility accreditation standards
• FDA medical-device requirements
• CMS and commercial payer coverage policies
• Occupational safety requirements
• Hyperbaric specialty accreditation standards

UHMS accreditation is generally voluntary, although an organization, insurer, contracting entity, or jurisdiction may expect or require accreditation as part of its own standards. Facilities remain responsible for complying with all applicable laws and codes regardless of whether they pursue specialty accreditation. (UHMS)

Medicare coverage is also separate from facility accreditation. CMS defines covered HBOT conditions and establishes requirements for medical necessity, standard care, documentation, and continued treatment. A UHMS-accredited program must still meet every applicable payer requirement for each patient and claim. (Centers for Medicare & Medicaid Services)

The UHMS Hyperbaric Facility Accreditation Framework

The UHMS accreditation process evaluates the program as an integrated clinical system. The Fourth Edition manual includes standards and survey expectations across areas such as:

• Hyperbaric patient care
• Environment of care
• Patient education
• Quality improvement
• Professional performance
• Leadership
• Human resources
• Information management
• Infection prevention
• Medical staff involvement

Survey documentation may include policies, training records, personnel files, medical records, maintenance reports, fire plans, emergency procedures, quality data, meeting minutes, and evidence that the written program is followed in practice. (UHMS)

Accreditation is therefore not achieved by purchasing compliant equipment or adopting a collection of generic policies. Surveyors evaluate whether responsibilities are clearly assigned, staff understand those responsibilities, records support the care delivered, and the program can demonstrate that risks are identified and corrected.

Medical Leadership and Clinical Governance

A hyperbaric program should have a clearly designated medical director with defined authority and accountability. The medical director provides clinical oversight and helps establish the program’s scope of care, patient-selection criteria, treatment protocols, provider privileges, emergency procedures, and quality expectations.

The leadership structure should answer practical questions such as:

• Who determines whether HBOT is clinically indicated?
• Who approves and modifies treatment protocols?
• Who reviews adverse events and questionable treatment continuation?
• Who verifies that physicians and advanced practice providers are appropriately privileged?
• Who coordinates care with surgery, vascular medicine, infectious disease, oncology, and other specialties?
• Who has authority to suspend treatment when a clinical concern is unresolved?

Medical staff participation should be visible in the program’s records. Accreditation documentation may include provider qualifications, hyperbaric education, continuing medical education, privileging criteria, peer-review activities, and evidence of active medical oversight. (UHMS)

The clinical scope should also match the program’s actual capabilities. A center treating stable outpatients requires different personnel and emergency resources from a hospital program accepting ventilated patients, arterial gas embolism, decompression illness, or necrotizing infection.

A facility should not claim emergency or critical-care capabilities simply because its chamber can physically accommodate the patient. The complete medical, respiratory, nursing, technical, and surgical support system must be available.

Staff Qualifications, Training, and Competency

Accreditation requires the facility to define the qualifications and responsibilities of every hyperbaric position. Job descriptions should reflect actual duties, professional scope of practice, reporting relationships, and emergency responsibilities.

The staffing framework may include:

• Hyperbaric medical director
• Attending hyperbaric physicians
• Advanced practice providers when permitted
• Registered nurses
• Licensed practical or vocational nurses
• Hyperbaric technologists
• Chamber operators
• Inside and outside attendants
• Respiratory therapists
• Hyperbaric safety director or coordinator
• Program leadership and administrative personnel

Personnel files should demonstrate current licensure, certification when applicable, orientation, chamber-specific training, annual competencies, continuing education, and performance evaluation. The accreditation manual specifically calls for documentation of job descriptions, orientation, in-service education, staff-performance review, specialty continuing education, and defined nursing activities. (UHMS)

Completion of a foundational course does not by itself establish operational competence. Staff should demonstrate the ability to prepare patients, operate the specific chamber system, recognize complications, manage prohibited items, respond to alarms, and perform assigned emergency functions.

Competency validation may include direct observation and simulation of:

• Routine compression and decompression
• Ear or sinus pain
• Hypoglycemia
• Oxygen toxicity
• Seizure
• Chest pain or respiratory distress
• Loss of communications
• Power or gas-supply failure
• Emergency decompression
• Fire response and evacuation

The accreditation documentation also expects evidence that the hyperbaric safety leader has completed appropriate hyperbaric safety education. The current manual’s supporting-document list includes verification of an approved safety course and timely specialty certification after assuming the role. (UHMS)

Hyperbaric Safety Leadership

A designated hyperbaric safety coordinator is a central component of the safety program. NFPA 99 identifies this individual as responsible for hyperbaric equipment and the operational safety requirements applicable to the facility. (UHMS)

The role commonly includes oversight of:

• Fire-prevention policies
• Chamber-approved materials
• Prohibited-item controls
• Product and dressing risk assessments
• Preventive maintenance
• Staff safety education
• Emergency drills
• Equipment changes
• Incident and near-miss review
• Coordination with engineering and fire-safety personnel

The safety coordinator should work closely with the medical director, but the positions are not interchangeable. The medical director is responsible for medical governance, while the safety coordinator focuses on the technical and operational risks of the hyperbaric environment.

The safety coordinator also needs sufficient organizational authority. A person cannot effectively protect the program if they are expected to approve equipment and practices but cannot remove an unsafe item, postpone treatment, or take a chamber out of service.

Facility Design and Environment of Care

Accreditation surveyors evaluate whether the physical environment supports safe chamber operation, patient monitoring, emergency access, and staff workflow.

The program should be able to demonstrate compliance with applicable building and fire codes and provide documentation for:

• Chamber installation
• Structural support
• Electrical systems and grounding
• Oxygen and compressed-air supplies
• Ventilation and exhaust
• Fire detection and suppression
• Medical gas alarms
• Emergency power
• Chamber visibility and communications
• Patient and stretcher access
• Emergency egress
• Storage of approved materials
• Environmental monitoring

FDA-cleared hyperbaric chambers are Class II medical devices. The FDA’s device classification references NFPA 99 and ASME PVHO-1 standards associated with hyperbaric chambers and pressure vessels for human occupancy. (FDA Access Data)

The facility must follow the manufacturer’s instructions for the exact chamber model and associated equipment. A device, accessory, or maintenance practice that is acceptable for one system should not automatically be assumed acceptable for another.

The accreditation manual also expects a medical-equipment management plan, hazardous-materials policies, fire-protection planning, and documentation that personnel understand their responsibilities during an evacuation. (UHMS)

Fire Prevention Is a Core Accreditation Requirement

The possibility of fire is one of the most consequential hazards in hyperbaric medicine. Oxygen does not ignite independently, but an oxygen-enriched environment can make materials easier to ignite and cause fire to spread more intensely.

In its August 25, 2025 safety communication, the FDA advised HBOT facilities to follow manufacturer instructions, maintain fire-prevention measures, use appropriate grounding, train staff, monitor patients continuously, perform prescribed maintenance, control electrical and static-producing items, and use hyperbaric-compatible clothing. (U.S. Food and Drug Administration)

An accreditable fire-safety program should address:

• Facility-approved patient clothing and linens
• Cosmetics, lotions, hair products, and alcohol-containing products
• Wound dressings
• Electronic and battery-powered devices
• Implanted and external medical equipment
• Static electricity and grounding
• Oxygen leaks and local oxygen enrichment
• Chamber cleaning
• Emergency gas shutoff
• Fire suppression
• Patient evacuation

Every item introduced into the chamber should be approved through a documented process. Routine hospital availability does not establish hyperbaric compatibility.

The program should also conduct and document realistic emergency drills. Staff should know who controls the chamber, who stops oxygen flow, who manages decompression, who contacts emergency responders, and who protects other patients in the department.

Preventive Maintenance and Equipment Management

Accreditation requires evidence that chambers and related systems are maintained according to manufacturer instructions, applicable standards, and facility policy.

The maintenance program should include:

• Preventive maintenance schedules
• Inspection records
• Corrective maintenance
• Calibration and functional testing
• Chamber door and seal evaluation
• Relief-valve testing
• Grounding-system checks
• Communication testing
• Gas-system inspection
• Alarm verification
• Fire-suppression maintenance
• Return-to-service authorization

The FDA specifically advises facilities to follow manufacturer-recommended cleaning procedures, maintenance intervals, and safety checks for each HBOT device. (U.S. Food and Drug Administration)

Maintenance records should show what was inspected, who performed the work, what findings were identified, which corrective actions were completed, and who authorized the chamber’s return to clinical service.

A defect should not be normalized because the chamber remains operational. Unusual sounds, pressure instability, damaged seals, communication failures, oxygen-delivery discrepancies, or alarm problems require documented evaluation.

Patient Selection and Hyperbaric Clinical Care

Accreditation surveyors examine whether patient care is organized, evidence based, and consistent with the program’s stated scope.

The medical record should support:

• A recognized or clinically defensible indication
• Relevant diagnostic findings
• Previous standard treatment
• Patient-specific risks and contraindications
• The treatment prescription
• Informed consent
• Pre-treatment assessment
• Monitoring during treatment
• Treatment response
• Adverse events
• Continued medical necessity
• Coordination with other treating clinicians

The treatment prescription should identify the pressure, oxygen duration, treatment frequency, air breaks when applicable, and planned reassessment. Deviations should be documented and clinically explained.

For qualifying diabetic lower-extremity wounds, CMS requires documentation of diabetes, a Wagner grade III or higher wound, failure of an adequate course of standard care, and continued use of vascular assessment, offloading, debridement, glucose management, infection treatment, nutrition, and appropriate wound care. CMS also requires periodic reassessment and does not support continued coverage without measurable healing during a 30-day treatment period. (Centers for Medicare & Medicaid Services)

This illustrates why accreditation and payer compliance must function together. An excellent chamber operation cannot compensate for weak patient selection or insufficient clinical documentation.

Patient Monitoring, Rights, and Education

Patients should receive understandable information about why HBOT is being recommended, what treatment involves, what alternatives exist, and what risks may occur.

Patient education should address:

• Pressure sensations and ear-clearing techniques
• Expected treatment duration
• Chamber communication
• Fire-safety restrictions
• Approved clothing
• Medication and glucose instructions
• Potential adverse effects
• Circumstances that may interrupt treatment
• Symptoms that should be reported immediately

The accreditation manual includes a dedicated patient-education section and expects written policies or procedures addressing how education is provided. (UHMS)

Education should be documented in the medical record and adapted to the patient’s language, cognitive ability, developmental level, and health literacy. Patients should be encouraged to report ear pain, anxiety, congestion, medication changes, glucose symptoms, or newly introduced devices and dressings.

A patient should never feel pressured to remain silent because stopping compression or interrupting treatment is inconvenient for the schedule.

Infection Prevention and Medication Management

Hyperbaric departments should be integrated into the organization’s infection-prevention system while addressing chamber-specific issues.

The accreditation manual calls for documentation describing the facility’s infection-prevention program. (UHMS)

Policies may address:

• Chamber and stretcher cleaning
• Reusable oxygen-delivery equipment
• Linen handling
• Isolation precautions
• Wound drainage
• Indwelling lines and catheters
• Respiratory infections
• Multiplace chamber exposure
• Blood and body-fluid events
• Equipment shared between patients

Medication policies should clarify which medications may be administered before or during treatment, how medications are stored, and how chamber compatibility is assessed.

Special attention may be required for insulin, oral glucose agents, sedatives, anticonvulsants, intravenous infusions, vasoactive medications, and drugs that may influence oxygen-toxicity risk or cardiorespiratory stability.

Medical Records and Information Management

Accreditation requires more than complete individual treatment notes. The program should demonstrate an organized information-management process that supports continuity of care, quality review, and regulatory compliance.

Records commonly include:

• Hyperbaric consultation
• Treatment order
• Informed consent
• Daily pre-treatment assessment
• Chamber treatment log
• Oxygen and air-break periods
• Monitoring data
• Post-treatment evaluation
• Adverse-event documentation
• Wound or condition-specific progress
• Communication with referring clinicians
• Discharge or treatment-completion summary

The accreditation manual’s information-management requirements include review of hyperbaric records for documentation quality and timely completion. Survey documentation may include reports and summaries demonstrating that this review has occurred over the preceding year. (UHMS)

A documentation audit should evaluate substance, not merely whether a note exists. The record should make clear why HBOT was appropriate, what treatment was delivered, how the patient responded, and why treatment should continue.

Quality Improvement Must Produce Measurable Results

A facility seeking accreditation should maintain a hyperbaric-specific quality-improvement program. General hospital quality activity is not enough when it does not evaluate the risks and outcomes unique to HBOT.

Potential measures include:

• Middle-ear barotrauma
• Oxygen-induced seizure
• Hypoglycemia
• Unplanned decompression
• Treatment interruption
• Chamber downtime
• Prohibited-item interception
• Emergency transfer
• Documentation compliance
• Treatment completion
• Clinical outcome by indication
• Patient complaints
• Near misses

The accreditation manual expects documentation showing the scope of quality-improvement initiatives and the results produced. Leadership should also be able to demonstrate how recommendations are assigned, acted upon, and communicated to staff. (UHMS)

A quality project should move beyond identifying a problem. The facility should define the baseline, implement an intervention, measure the result, and determine whether the change was sustained.

Near misses are particularly valuable. An unapproved item discovered before treatment, an incorrect profile caught during the safety pause, or a maintenance discrepancy identified before chamber use may reveal a system weakness without patient harm.

The UHMS Application and Survey Process

The UHMS process begins with an application, presurvey questionnaire, and supporting documentation submitted through its accreditation platform. UHMS reviews the program’s materials before the formal survey. (UHMS)

The survey may include:

• Review of policies and personnel records
• Inspection of the physical environment
• Evaluation of equipment and maintenance records
• Interviews with leadership and staff
• Review of clinical records
• Observation of patient preparation and treatment
• Assessment of emergency readiness
• Review of quality and safety activities

UHMS surveyors collect information and report their findings, but the survey team does not make the final accreditation decision during the visit. (UHMS)

Programs may be asked to address identified deficiencies through corrective action. The safest approach is to treat each finding as a clinical or operational risk rather than as paperwork needed only to satisfy the accrediting body.

Accredited facilities must also maintain compliance after the survey. Material changes in chamber systems, facility location, leadership, clinical scope, or ownership may affect accreditation status and should be communicated according to current UHMS requirements. (UHMS)

Accreditation With Distinction

UHMS also provides an advanced “With Distinction” pathway for facilities meeting additional criteria beyond core accreditation.

Current guidance includes enhanced expectations related to medical-director qualifications and other markers of professional engagement and program excellence. Some criteria must be active at the time of survey, while others may be demonstrated through activity completed during a defined period before the survey. (UHMS)

This designation should be approached after the facility has built a stable foundation. Strong daily operations, reliable safety systems, complete records, and measurable quality performance remain more important than pursuing an advanced designation before core processes are mature.

Common Accreditation Readiness Gaps

Programs often struggle when written policies do not match actual practice.

Common vulnerabilities include:

• Expired credentials or incomplete personnel files
• Generic policies that do not match the chamber system
• Missing competency validation
• Inadequate safety-director documentation
• Poorly defined provider privileges
• Incomplete maintenance records
• No formal product-approval process
• Fire drills that are undocumented or unrealistic
• Weak medical-necessity documentation
• Quality projects without measured results
• Inconsistent review of treatment continuation
• Staff who cannot explain emergency responsibilities

Survey readiness should include direct observation. Leadership should watch the complete process from referral and consultation through patient preparation, chamber treatment, documentation, billing, and follow-up.

The most revealing question is often not, “Do we have a policy?” It is, “Can the staff demonstrate the policy without being coached?”

Building a Sustainable Accreditation Program

A practical readiness plan should begin with the current accreditation manual and a detailed internal gap assessment.

The program should then:

1. Assign responsibility for each standard.
2. Review facility, personnel, and clinical documentation.
3. Correct physical and equipment deficiencies.
4. Update policies to reflect actual operations.
5. Validate staff competencies.
6. Conduct realistic emergency drills.
7. Audit patient records and medical necessity.
8. Complete measurable quality-improvement projects.
9. Perform a mock survey.
10. Maintain the system after accreditation is awarded.

The goal is not a survey-day performance. It is a program that operates safely and consistently when the surveyors are not present.

For patients, accreditation provides an additional level of assurance that the center has subjected its clinical and technical systems to external review. For hospitals and healthcare organizations, it establishes a structured framework for managing a specialized service with significant medical, pressure, oxygen, and fire-safety risks.

Building a Qualified Clinical, Technical, and Safety Team for Monoplace and Multiplace Operations

Staffing a hyperbaric center requires more than assigning personnel to operate a chamber. Hyperbaric oxygen therapy combines medical treatment, pressure-vessel operations, oxygen fire safety, continuous patient observation, and emergency response within an environment that limits immediate physical access to the patient.

The appropriate staffing model depends on the chamber type, number of patients treated simultaneously, patient acuity, accepted clinical indications, operating hours, and the facility’s ability to provide emergency and critical care. A center treating stable outpatients in monoplace chambers has different requirements from a hospital program treating ventilated patients in a multiplace chamber.

Staffing ratios should be treated as minimum safety parameters, not productivity targets. The medical director and hyperbaric safety leadership should increase staffing whenever patient complexity, staff experience, equipment needs, or emergency responsibilities make the minimum ratio insufficient.

Hyperbaric Medical Director Responsibilities

Every clinical hyperbaric program should have a qualified physician medical director who provides oversight for the medical use of hyperbaric oxygen.

The medical director is generally responsible for:

• Establishing patient-selection criteria
• Approving treatment protocols
• Defining provider privileges
• Supervising clinical quality
• Reviewing adverse events and near misses
• Developing emergency procedures
• Overseeing provider education and proctorship
• Coordinating with hospital leadership and referring specialists
• Ensuring treatment remains medically appropriate

The Undersea and Hyperbaric Medical Society, or UHMS, recommends that a hyperbaric medical director meet the qualifications required of an independent hyperbaric supervisor. Board certification in Undersea and Hyperbaric Medicine is strongly encouraged, particularly for leadership roles and programs managing high-acuity patients. UHMS also advises against assigning hyperbaric medical-director responsibility to a physician whose training is limited to wound care without additional education and experience in hyperbaric medicine. (UHMS)

The medical director does not necessarily need to be physically present for every administrative function, but the program must have qualified clinical coverage whenever patients are undergoing treatment. The medical director should also ensure that privileges are limited to the indications, chamber configurations, and patient-acuity levels each provider is trained to manage. (UHMS)

Physician or Qualified Provider Attendance

Hyperbaric oxygen therapy is a medical procedure that requires appropriate clinical attendance and supervision throughout the treatment session.

The attending provider should be able to:

• Confirm the indication and treatment prescription
• Evaluate the patient before treatment
• Identify new contraindications or clinical instability
• Modify or terminate the treatment when necessary
• Manage oxygen toxicity, barotrauma, chest pain, neurologic symptoms, hypoglycemia, and other complications
• Coordinate emergency decompression and transfer
• Document the treatment and patient response

CMS recognizes physician attendance and supervision of HBOT under CPT code 99183. Current Medicare coding guidance states that the code includes the evaluation and management work directly related to the hyperbaric treatment. (CMS Downloads)

UHMS guidance states that hyperbaric treatments should be prescribed and supervised by qualified clinicians with appropriate training. The attending provider must remain immediately available to the chamber throughout the treatment session. The physical separation created by a pressurized chamber makes it essential that the provider can rapidly identify and manage systemic complications. (UHMS)

Advanced practice providers may attend HBOT under defined circumstances when permitted by state law, hospital bylaws, payer rules, scope-of-practice requirements, and collaborative agreements. Current UHMS guidance requires appropriate hyperbaric education, proctored experience, facility privileges, immediate availability to the chamber, and physician backup with a reasonable in-person response time. The physician retains responsibility for ensuring that the patient’s complexity can be managed safely under that supervision model. (UHMS)

Programs should verify current state and payer requirements rather than assuming that one supervision model applies nationally.

Hyperbaric Provider Training and Privileging

Completion of a foundational hyperbaric medicine course is only the beginning of provider preparation. UHMS-approved foundational courses include at least 40 hours of hyperbaric-specific education, equipment familiarization, assessment, and practical instruction. (UHMS)

Providers should also complete a documented proctorship before independently attending treatments. The April 2026 UHMS credentialing guideline recommends at least five proctored consultations and attendance of more than 25 hyperbaric sessions, followed by review of the next 100 treatments through an appropriate professional-practice evaluation process. (UHMS)

Privileges should specify:

• Which hyperbaric indications the provider may treat
• Whether the provider may manage stable or critically ill patients
• Which chamber types the provider may supervise
• Whether pediatric or ventilated patients are included
• Any procedures the provider may perform
• Required backup or proctoring arrangements

UHMS recommends that privileges be granted according to demonstrated education, licensure, experience, patient acuity, and the technical capabilities of the facility. A provider qualified to attend stable outpatient treatments should not automatically be privileged to manage ventilated or hemodynamically unstable patients. (UHMS)

Continued competency also requires ongoing clinical activity and education. The 2026 UHMS guideline recommends at least 12 hours of relevant continuing medical education each year, or 24 hours over two years, along with evidence of recent hyperbaric clinical experience. (UHMS)

The Role of the Hyperbaric Registered Nurse

Registered nurses are central to many hospital and outpatient hyperbaric programs. Their responsibilities often extend across patient assessment, treatment preparation, wound care, chamber operation, education, monitoring, and emergency response.

Depending on facility policy and individual qualifications, a hyperbaric nurse may perform:

• Pre-treatment clinical assessment
• Medication reconciliation
• Vital-sign monitoring
• Blood glucose testing and management
• Patient and family education
• Evaluation of pressure-equalization concerns
• Wound assessment and documentation
• Management of vascular access and approved infusions
• Chamber operation
• Inside-attendant duties
• Recognition of oxygen toxicity and clinical deterioration
• Post-treatment assessment

Hyperbaric nursing requires knowledge that extends beyond routine wound care. Nurses must understand gas behavior, pressure-related injury, oxygen toxicity, fire safety, chamber operations, emergency decompression, and the effects of pressure on medical equipment.

UHMS materials recognize registered nurses and licensed practical nurses among the healthcare professionals who may work as chamber operators or inside attendants when appropriately educated, trained, and authorized by the facility. (UHMS)

Certification as a Certified Hyperbaric Registered Nurse can provide evidence of specialty knowledge and professional development. Certification does not replace facility-specific orientation, competency validation, or compliance with nursing scope-of-practice requirements.

Hyperbaric Technologists and Chamber Operators

The chamber operator manages the technical execution of the prescribed treatment. This role requires continuous attention throughout compression, time at treatment pressure, oxygen-breathing periods, air breaks, and decompression.

Operator responsibilities may include:

• Verifying the prescribed treatment profile
• Conducting operational safety checks
• Controlling compression and decompression
• Monitoring chamber pressure and gas systems
• Maintaining communication with the patient or inside attendant
• Recording treatment events
• Responding to alarms and equipment abnormalities
• Supporting emergency procedures
• Completing post-treatment equipment checks

The operator must understand both normal chamber function and the consequences of equipment or human error under pressure.

For monoplace facilities, an often-cited industry benchmark is one chamber operator for every two operating chambers. This should not be interpreted as a universal regulatory limit or as permission to operate two chambers regardless of patient condition. A patient with significant medical instability, communication difficulty, anxiety, airway risk, or complex equipment may require dedicated one-to-one observation. (UHMS)

The operator ratio also does not replace the need for nursing assessment, provider attendance, safety oversight, or personnel available to respond to an emergency. One person should not be expected to operate chambers, prepare incoming patients, discharge completed patients, perform wound care, and manage an emergency simultaneously.

Certification as a Certified Hyperbaric Technologist is commonly used to demonstrate specialty competency. UHMS and the National Board of Diving and Hyperbaric Medical Technology provide certification pathways for hyperbaric technologists and registered nurses. (UHMS)

Monoplace Hyperbaric Chamber Staffing

A monoplace chamber treats one patient at a time, with staff remaining outside the chamber. This arrangement may appear less staffing intensive than multiplace operation, but the physical barrier between the patient and staff creates its own safety demands.

A basic monoplace treatment team commonly includes:

• A qualified attending provider
• A trained chamber operator
• A nurse or other clinical professional capable of assessing the patient and responding to complications
• Access to the hyperbaric safety director or designated safety personnel
• Additional support for patient transfer, emergency care, or complex equipment when required

Several chambers may be operated within one treatment area, but the facility must preserve uninterrupted visual and verbal observation of each patient. Staffing must also account for staggered compression and decompression, patient preparation, glucose checks, bathroom needs, wound dressings, and post-treatment assessment.

A two-chamber assignment may be reasonable for stable, communicative patients undergoing routine protocols. The ratio should be reduced when a patient:

• Is medically unstable
• Requires continuous cardiovascular monitoring
• Has a difficult airway
• Is ventilated
• Requires intravenous medication or complex equipment
• Has significant anxiety or cognitive impairment
• Cannot report symptoms reliably
• Is receiving an urgent treatment
• Has a history of oxygen toxicity or pressure intolerance

A center should not calculate monoplace staffing solely by dividing the number of chambers by two. The actual workload includes patients outside the chamber who are being prepared, evaluated, or discharged.

Multiplace Hyperbaric Chamber Staffing

A multiplace chamber requires both internal and external personnel. Patients are generally treated inside an air-pressurized chamber while breathing oxygen through masks, hoods, or airway circuits.

UHMS minimum-staffing guidance identifies a core operational team that includes:

• One chamber operator
• At least one inside attendant
• At least one outside attendant who is available to support the chamber operation

These roles should be assigned before treatment begins and should not be combined in a way that leaves a critical responsibility unattended. (UHMS)

The number of inside attendants should reflect the needs of the patients under pressure. UHMS guidance identifies a minimum patient-to-attendant ratio of approximately 6:1 for uncomplicated ambulatory patients and 4:1 for patients requiring an increased level of personal care. (UHMS)

For intubated or severely ill acute-care patients, the recommended ratio is one inside attendant per patient. Some patients may require more than one attendant because of ventilation, infusion management, positioning, behavioral needs, or the potential for rapid deterioration. Direct access to a hyperbaric-trained physician is mandatory during treatment of critically ill or intubated patients. (UHMS)

These ratios are minimums. A chamber containing several ambulatory patients and one unstable patient should be staffed according to the most resource-intensive patient, not simply according to the total census.

Inside Attendant Qualifications and Medical Fitness

The inside attendant remains under pressure with patients and provides direct clinical assistance during the treatment.

Depending on patient needs, the attendant may:

• Fit and monitor oxygen masks or hoods
• Assist with ear-pressure equalization
• Manage airway or ventilator equipment
• Administer approved medications
• Monitor infusions
• Respond to anxiety, nausea, pain, or neurologic symptoms
• Perform emergency interventions
• Coordinate with the chamber operator and attending provider

Because inside attendants are repeatedly exposed to increased ambient pressure, they require medical fitness assessment and occupational exposure management. Current UHMS guidance addresses the medical fitness of multiplace inside attendants and recommends involvement of a physician with appropriate hyperbaric training in determining fitness for pressure exposure. (UHMS)

Scheduling should account for cumulative pressure exposure, decompression requirements, pregnancy policies, respiratory illness, medication changes, and other conditions that may affect an attendant’s fitness to enter the chamber.

An employee who is unavailable for inside-attendant duty because of illness or medical restriction should not be counted toward the minimum chamber staffing level.

The Outside Attendant and Emergency Support Role

The outside attendant supports the chamber team while remaining available in the treatment area. This individual may help manage gas systems, equipment transfer, patient records, emergency supplies, communications, and coordination with hospital responders.

The outside attendant is particularly important during:

• Medical deterioration inside the chamber
• Emergency decompression
• Equipment or gas-supply failure
• Transfer of supplies through a medical lock
• Fire or evacuation
• Communication failure
• Staff replacement or occupational decompression issues

The chamber operator should not be expected to leave the controls to obtain emergency equipment or summon assistance. Similarly, the attending provider should not be the only person available outside the chamber to manage all operational and clinical duties.

Hyperbaric Safety Director or Safety Coordinator

Every hyperbaric program should designate an individual responsible for coordinating the facility’s technical and fire-safety program.

Responsibilities commonly include:

• Reviewing items proposed for chamber use
• Maintaining prohibited-item controls
• Coordinating preventive maintenance
• Overseeing fire-safety education
• Verifying staff competencies
• Planning and evaluating emergency drills
• Reviewing incidents and near misses
• Participating in equipment purchasing
• Managing chamber-specific safety policies
• Coordinating with facilities, engineering, and the fire authority

The title may be Hyperbaric Safety Director or Hyperbaric Safety Coordinator depending on organizational authority and reporting structure. The essential requirement is that the individual has clearly defined responsibility and enough authority to remove unsafe equipment, prohibit an item, or stop a treatment when a safety concern has not been resolved. (UHMS)

This role should not exist only on paper. The safety professional needs protected time for product review, education, drills, preventive maintenance oversight, and policy development.

UHMS accreditation is designed to evaluate staffing, safety systems, training, equipment, and the professional application of hyperbaric treatment. Building staffing policies around recognized accreditation requirements helps a program move beyond informal, person-dependent practices. (UHMS)

Respiratory Therapy and Critical Care Staffing

A program treating ventilated, sedated, or hemodynamically unstable patients requires staff with critical-care competencies in addition to routine hyperbaric training.

The team may need:

• A respiratory therapist
• A critical-care nurse
• A physician experienced in critical illness
• Additional inside attendants
• Pharmacy and infusion support
• Immediate access to anesthesia, emergency medicine, surgery, or intensive care

Ventilator performance, airway-cuff pressure, infusion delivery, gas-filled components, and monitoring equipment can change under pressure. Staff must understand how the specific equipment behaves within the planned treatment environment.

The April 2026 UHMS credentialing guideline separates privileges for stable-patient attendance from privileges for critical-care HBOT. Providers managing critical-care patients should be competent in continuous cardiac monitoring, intravenous infusions, hemodynamic support, and mechanical ventilation. The facility must also have the technical and logistical capability to provide that care under pressure. (UHMS)

A center should not accept ventilated or unstable patients because the chamber can physically accommodate them. It should do so only when the complete clinical team can maintain an appropriate level of care throughout transport, chamber treatment, and emergency decompression.

Wound Care and Supporting Clinical Personnel

Many hyperbaric programs are integrated with wound-care services. This creates opportunities for coordinated care, but wound-clinic staffing and hyperbaric staffing should not be treated as interchangeable.

A wound-care clinician may be occupied with debridement, dressing selection, vascular assessment, or another patient while chamber treatments are underway. The center must ensure that hyperbaric observation and emergency responsibilities remain continuously covered.

Supporting clinical personnel may include:

• Wound-care nurses
• Medical assistants
• Podiatric or surgical clinicians
• Vascular laboratory personnel
• Dietitians
• Diabetes educators
• Infectious disease specialists
• Rehabilitation staff
• Case managers

These professionals improve the broader care plan but generally do not replace the chamber operator, attending provider, inside attendant, or safety personnel required for active HBOT.

Administrative and Revenue-Cycle Staffing

A sustainable hyperbaric center also requires administrative support. Treatment courses may involve prior authorization, payer-specific documentation, daily scheduling, transportation challenges, and repeated reassessment.

Administrative roles may include:

• Program manager
• Scheduler
• Prior-authorization specialist
• Medical-records or documentation support
• Revenue-cycle specialist
• Referral coordinator
• Quality and accreditation support

CMS covers HBOT only for specified conditions and applies additional requirements to certain indications. Administrative personnel should understand the difference between a referral, a clinically appropriate treatment, and a reimbursable treatment under a particular payer policy. (Centers for Medicare & Medicaid Services)

Insufficient administrative staffing can create clinical problems. Authorization delays may postpone time-sensitive treatment, incomplete records may prevent proper patient selection, and poor scheduling may create unsafe overlap between complex patients.

After-Hours and Emergency Coverage

A center advertising 24-hour emergency capability needs more than an on-call physician.

The emergency staffing plan should identify:

• Who activates the chamber team
• Who operates the chamber
• Who serves as inside and outside attendant
• Who provides physician attendance
• How respiratory therapy and critical care support are obtained
• Who prepares the chamber and safety equipment
• How surgery, emergency medicine, and intensive care are coordinated
• What happens when key personnel are unavailable

Emergency indications such as carbon monoxide poisoning, arterial gas embolism, decompression sickness, necrotizing infection, or acute traumatic ischemia may involve unstable patients and time-sensitive decisions.

Current UHMS guidance permits qualified advanced practice providers to support 24-hour coverage only under defined credentialing and physician-backup conditions. A physician qualified as an independent hyperbaric supervisor must remain available by telephone and be able to respond in person within the period established by hospital policy. (UHMS)

The program should conduct unannounced or realistic after-hours drills. A coverage schedule that appears adequate during business hours may fail when staff must travel from home, locate chamber-compatible equipment, and coordinate with an emergency department at night.

Competency Validation and Emergency Drills

Staffing numbers alone do not establish readiness. Every person assigned to the chamber area must understand their role during normal and emergency operations.

Competency validation should include:

• Chamber startup and shutdown
• Treatment-profile verification
• Compression and decompression
• Oxygen-delivery systems
• Fire prevention
• Prohibited-item screening
• Ear and sinus pressure problems
• Oxygen-toxicity response
• Hypoglycemia
• Chest pain and respiratory distress
• Cardiac arrest
• Seizure management
• Gas-supply or power failure
• Emergency decompression
• Evacuation
• Equipment malfunction

Competency should be evaluated through direct observation and simulation, not only through completion of an online module or attendance certificate.

The FDA advises hyperbaric facilities to maintain staff training, continuously monitor patients, follow manufacturer operating instructions, perform required maintenance, and maintain fire-prevention procedures. (Mayo Clinic)

Drills should test communication and decision-making as well as individual technical skills. The team should know who controls the chamber, who manages the patient, who calls the emergency response team, and who protects the other patients in the facility.

Buildi£ng a Staffing Matrix for the Center

A useful staffing plan should define minimum coverage for each chamber configuration and patient-acuity category.

The matrix may include separate plans for:

• Stable monoplace outpatients
• Multiple simultaneous monoplace treatments
• Patients requiring continuous monitoring
• Pediatric or cognitively impaired patients
• Stable multiplace groups
• High-dependency multiplace patients
• Intubated or critically ill patients
• Emergency and after-hours treatments
• Treatments involving inside attendants
• Planned maintenance or reduced chamber availability

For each scenario, the matrix should specify:

• Attending provider
• Chamber operator
• Registered nurse
• Inside attendant
• Outside attendant
• Respiratory therapist
• Safety coverage
• Emergency backup
• Maximum patient census

The matrix should also define when staffing must be increased. Triggers may include a new ventilated patient, staff inexperience, multiple high-risk patients, complex oxygen-delivery equipment, emergency transfers, or simultaneous treatment and wound-care activity.

Staffing for Safety Rather Than Maximum Throughput

Hyperbaric staffing should be designed around the team’s ability to recognize deterioration and act immediately. A chamber may continue operating normally while the patient develops hypoglycemia, chest pain, oxygen toxicity, respiratory distress, or an anxiety reaction. The staff must notice the change, interpret it correctly, and respond without abandoning other patients.

A center should reconsider its staffing model when personnel routinely:

• Monitor more patients than they can observe continuously
• Leave chamber controls unattended
• Perform wound procedures while operating chambers
• Rely on administrative personnel for clinical observation
• Combine inside, outside, and operator responsibilities unsafely
• Lack immediate backup during emergencies
• Work without current competency validation
• Depend on one individual whose absence closes the program

The required headcount is not determined solely by the number of chambers. It is determined by the clinical responsibilities that must remain covered at the same time.

A well-staffed hyperbaric center has clear medical leadership, trained chamber personnel, nursing support, active safety oversight, and scalable critical-care resources. It also maintains enough redundancy to respond when a patient deteriorates, equipment fails, or an employee becomes unavailable.

How Hospitals Can Evaluate Revenue, Utilization, Capital Costs, Compliance Risk, and Long-Term Service-Line Value

A hospital-based hyperbaric medicine program can generate meaningful clinical and financial value, but profitability is not created by chamber ownership alone. Return on investment depends on whether the organization has an appropriate patient population, a defensible referral base, sufficient chamber utilization, disciplined cost control, and documentation that consistently supports medical necessity.

Hyperbaric oxygen therapy is also a resource-intensive service. Programs require specialized chambers, oxygen and compressed-air infrastructure, trained clinical personnel, physician supervision, preventive maintenance, fire-safety systems, payer authorization, and ongoing quality oversight. A business model that focuses only on reimbursement per treatment can substantially overstate the expected return.

A credible financial analysis should connect program economics to clinical appropriateness. The objective is not to maximize the number of treatments delivered. It is to build a service that treats eligible patients safely, produces measurable outcomes, and remains financially sustainable.

Hyperbaric Program ROI Is More Than Treatment Revenue

The basic financial calculation is straightforward:

ROI = Annual financial return ÷ Total invested capital

The difficult part is determining what should count as financial return and which costs belong in the denominator.

A hyperbaric program may generate value through:

• Hospital outpatient facility reimbursement
• Professional reimbursement for physician attendance and supervision
• Increased use of related wound, vascular, surgical, imaging, and rehabilitation services
• Retention of patients who might otherwise leave the health system
• Reduced dependence on external hyperbaric referrals
• Potential avoidance of preventable admissions, complications, or major procedures
• Strategic support for oncology survivorship, limb preservation, trauma, and surgical reconstruction

Not every category should be treated as direct revenue. Avoided costs and downstream service-line value should be reported separately from the program’s operating margin. Mixing these categories can make a financially weak program appear profitable or cause leadership to double count the same economic benefit.

A useful business case should show three distinct views:

1. Direct hyperbaric operating performance
2. Downstream health-system contribution
3. Potential cost avoidance associated with improved clinical outcomes

This structure allows executives to understand whether the chamber service is financially self-sustaining and whether it creates broader organizational value.

How Hyperbaric Oxygen Therapy Is Reimbursed

In a hospital outpatient department, the technical component of full-body chamber treatment is generally reported with HCPCS code G0277, which describes hyperbaric oxygen under pressure per 30-minute interval. CMS states that G0277 is used for the hospital outpatient facility service and is not available for use in other settings in the same manner. Physician attendance and supervision are generally reported per session with CPT code 99183. (Centers for Medicare & Medicaid Services)

The distinction matters because the hospital and physician revenue streams are different:

• Facility revenue is associated with the chamber treatment and hospital outpatient payment methodology.
• Professional revenue is associated with the physician’s attendance and supervision of the treatment session.
• Other wound or medical services may be separately reportable only when they are medically necessary, properly documented, and not bundled into the hyperbaric service.

CMS coding policy states that the evaluation and management work related to the hyperbaric treatment is included in CPT 99183. A separate evaluation and management service should not be assumed to be billable simply because the patient was seen by a physician on the treatment date. (Centers for Medicare & Medicaid Services)

Payment rates vary by year, payer, hospital status, geographic locality, contract terms, and site of service. The 2026 Medicare Physician Fee Schedule lookup tool applies geographic adjustments to professional payment, while hospital outpatient rates are governed through the annual Outpatient Prospective Payment System. Organizations should use their own contract terms and current CMS files rather than inserting a national reimbursement estimate into the financial model. (Centers for Medicare & Medicaid Services)

Covered Indications Determine the Financially Addressable Market

A hospital should not estimate hyperbaric demand by counting every patient with a chronic wound, infection, radiation history, or postoperative complication.

Medicare’s National Coverage Determination limits reimbursement to specified conditions, including carbon monoxide poisoning, decompression illness, gas embolism, gas gangrene, acute traumatic peripheral ischemia, selected compromised grafts, chronic refractory osteomyelitis, soft tissue radionecrosis, osteoradionecrosis, and qualifying diabetic lower-extremity wounds. (Centers for Medicare & Medicaid Services)

Commercial payer policies may differ from Medicare and from one another. Some require prior authorization, additional diagnostic testing, specialist documentation, or adherence to specific treatment limits.

The distinction between clinical prevalence and reimbursable demand is especially important for diabetic foot ulcers. Medicare coverage generally requires:

• Type 1 or type 2 diabetes
• A lower-extremity wound related to diabetes
• Wagner grade III or higher
• Failure of at least 30 days of standard wound therapy
• Continued comprehensive wound care during HBOT

The wound must be reassessed at least every 30 days. Continued Medicare coverage is not supported when measurable healing has not been demonstrated within a 30-day treatment period. (Centers for Medicare & Medicaid Services)

A market analysis that counts superficial diabetic ulcers, uncomplicated surgical wounds, or noncovered wellness indications will materially overstate eligible volume.

Chamber Utilization Drives Financial Performance

Hyperbaric programs typically carry substantial fixed costs. Once the facility is open, many expenses remain relatively stable whether a chamber treats two patients or six patients during the day.

Utilization therefore has a major effect on contribution margin.

Important variables include:

• Number of installed chambers
• Available operating hours
• Average treatments per chamber per day
• Average treatment length
• Number of billable 30-minute intervals
• Scheduled versus completed sessions
• Patient cancellation and no-show rates
• Chamber downtime
• Emergency or maintenance closures
• Average number of treatments per patient
• Time required for preparation, compression, decompression, and turnover

A chamber should not be modeled as though every operating hour is billable. Patient preparation, glucose management, ear-clearing difficulty, emergency interruptions, cleaning, safety checks, and maintenance all reduce practical capacity.

The program should calculate both theoretical and achievable capacity. A realistic model may assume a gradual ramp rather than immediate full utilization.

A practical measure is:

Chamber utilization = Completed chamber hours ÷ Available chamber hours

The hospital should also track completed treatments per staffed chamber day. This reveals whether low volume results from inadequate referrals, inefficient scheduling, patient cancellations, or excessive downtime.

Patient Completion Rates Affect Revenue and Outcomes

Many chronic hyperbaric indications require daily treatment over several weeks. Patients may need transportation five days per week while also attending wound, vascular, surgical, oncology, or urology appointments.

A referral does not automatically become a completed course.

Completion may be affected by:

• Transportation barriers
• Work or caregiver obligations
• Treatment fatigue
• Hospitalization
• Glucose instability
• Ear or sinus problems
• Claustrophobia
• Insurance authorization delays
• Out-of-pocket costs
• Failure to demonstrate continued clinical benefit

Financial projections should distinguish among:

• Referred patients
• Clinically eligible patients
• Authorized patients
• Patients who begin treatment
• Completed treatment sessions
• Completed treatment courses

Using referral volume as treatment volume can substantially overestimate revenue. A program with compassionate scheduling, transportation support, clear patient education, and strong care coordination may improve both clinical adherence and financial performance.

Capital Costs Extend Beyond the Hyperbaric Chambers

The chamber purchase is only one component of startup investment.

Capital planning may include:

• Monoplace or multiplace chambers
• Construction and structural modifications
• Oxygen and compressed-air systems
• Ventilation and exhaust
• Electrical and grounding systems
• Fire detection and suppression
• Emergency power
• Medical gas alarms
• Patient monitoring equipment
• Chamber-compatible stretchers and accessories
• Control stations and communication systems
• Wound assessment and transcutaneous oxygen equipment
• Architectural, engineering, permitting, and commissioning fees

A multiplace installation may create a substantially different capital and staffing model from a group of monoplace chambers. The correct choice depends on the intended patient acuity, referral volume, emergency capability, and hospital strategy rather than the lowest initial purchase price.

The capital model should also include financing costs, depreciation, useful life, anticipated replacement, and the effect of future expansion.

Fixed Operating Expenses Must Be Modeled Honestly

Fixed and semi-fixed expenses commonly include:

• Medical director compensation
• Nursing and technologist staffing
• Program management
• Hyperbaric safety oversight
• Physician coverage arrangements
• Service contracts
• Preventive maintenance
• Equipment inspections
• Staff training and competency validation
• Accreditation costs
• Information technology and documentation systems
• Insurance and risk-management costs
• Facilities and engineering support
• Revenue-cycle and prior-authorization personnel

Staffing should not be reduced below safe operational requirements merely to improve the spreadsheet. Hyperbaric facilities require qualified personnel, clearly defined medical leadership, maintenance systems, and ongoing competency programs. UHMS accreditation evaluates equipment, staff, training, safety systems, and quality of care rather than chamber volume alone. (UHMS)

A business case that excludes safety, maintenance, education, and emergency readiness is not measuring the cost of a functioning medical program.

Variable Costs Should Be Calculated Per Completed Treatment

Variable expenses increase as treatment volume rises. They may include:

• Oxygen and compressed air
• Disposable breathing interfaces
• Chamber-approved linens and patient garments
• Wound and line protection supplies
• Glucose-testing supplies
• Cleaning materials
• Incremental clinical labor
• Physician supervision expense
• Billing and collection costs
• Equipment wear associated with use

The organization should calculate variable cost per completed session and per completed course.

This allows the program to determine:

Contribution margin per treatment = Net collected revenue per treatment − Variable cost per treatment

The contribution margin is then available to cover fixed costs and capital investment.

Charges should not be used as a substitute for expected collections. The model should use contractual allowed amounts, historical collection rates, patient responsibility, denial rates, and expected bad debt.

Break-Even Analysis Should Use Completed Treatments

The basic break-even calculation is:

Break-even treatments = Annual fixed operating costs ÷ Contribution margin per completed treatment

The result should then be translated into:

• Treatments per year
• Treatments per month
• Treatments per staffed day
• Average active patients required
• Required chamber utilization

For example, if an average patient completes a multweek course, the organization should calculate how many new patients must begin each month to maintain the required daily census.

A treatment-based break-even model is generally more reliable than a patient-based model because different indications require different numbers of sessions. A radiation-injury patient may receive a substantially different treatment course from a patient treated for a compromised flap or carbon monoxide poisoning.

Build Conservative, Expected, and Upside Scenarios

A single forecast can conceal substantial uncertainty. Hospitals should model at least three scenarios.

The conservative case should assume:

• Slower referral growth
• Lower treatment completion
• Higher cancellation rates
• More authorization denials
• Lower contractual reimbursement
• Higher staffing or oxygen expense
• More chamber downtime

The expected case should use documented referral patterns, payer contracts, staffing plans, and realistic ramp assumptions.

The upside case may reflect stronger referral conversion or improved utilization, but it should not depend on noncovered indications, automatic authorization, or unsafe reductions in staffing.

Each scenario should show:

• Startup capital
• Annual net revenue
• Annual operating expense
• Contribution margin
• Operating income
• Break-even date
• Cash payback period
• Sensitivity to volume and payment changes

The most informative sensitivity analysis often changes treatment volume, payer mix, collected revenue per treatment, and staffing cost. These variables usually influence the result more than small changes in supply expense.

Compliance Risk Is a Financial Variable

Medical necessity and documentation are not administrative details added after the business model is complete. They are central financial assumptions.

Federal audits have identified substantial payment errors involving HBOT. In one 2018 Office of Inspector General audit, 102 of 120 sampled outpatient claims paid by a Medicare contractor did not comply with Medicare requirements, resulting in more than $300,000 in identified overpayments. A separate contractor audit found noncompliance in 110 of 120 sampled claims. (HHS Inspector General)

The federal government has also resolved False Claims Act allegations involving medically unnecessary HBOT billing. These enforcement actions demonstrate that high treatment volume without strong medical-necessity controls can create repayment, penalty, and reputational risk rather than sustainable profit. (HHS Inspector General)

Financial planning should account for:

• Prior-authorization denials
• Medical-necessity denials
• Documentation deficiencies
• Failure to meet continued-coverage criteria
• Coding errors
• Recoupment risk
• External audit expense
• Compliance monitoring
• Professional and facility billing alignment

The program should audit records before claims submission and periodically review treatment continuation. A treatment course should stop when it is no longer clinically appropriate, even when additional sessions were originally planned.

Physician Alignment Influences Program Economics

Professional coverage can be structured through employed physicians, contracted physicians, a hospital medical group, or another compliant arrangement.

The financial model should clarify:

• Who provides treatment supervision
• How physicians are compensated
• Who bills CPT 99183
• Whether coverage is available throughout operating hours
• How urgent and inpatient cases will be managed
• How vacation and after-hours coverage will be maintained
• Who performs consultations and continued-treatment assessments

Compensation should support medical oversight without creating incentives for unnecessary treatment.

The medical director also contributes value that may not appear in professional claims. Protocol development, utilization review, emergency planning, staff education, peer review, and quality oversight require protected time and should be included in program expense.

Downstream Value Can Strengthen the Hospital Business Case

Hyperbaric medicine often functions as part of a broader clinical network. A well-integrated program may support:

• Limb-preservation services
• Vascular and endovascular care
• Podiatric and orthopedic surgery
• Infectious disease
• Radiation oncology survivorship
• Urology and colorectal surgery
• Head and neck oncology
• Plastic and reconstructive surgery
• Emergency medicine and trauma
• Rehabilitation and prosthetic care

The hospital may retain diagnostic imaging, laboratory services, surgery, wound care, infusion therapy, rehabilitation, and specialist visits that would otherwise occur outside the system.

This downstream value should be attributed carefully. The program should count only services reasonably connected to the hyperbaric referral pathway and should avoid assigning the full value of an unrelated hospitalization or surgery to HBOT.

A useful reporting structure separates:

• Direct HBOT net revenue
• Direct HBOT operating margin
• Attributable downstream contribution margin
• Documented cost avoidance
• Strategic or community value that cannot be reliably monetized

Clinical Outcomes Should Be Included in the ROI Dashboard

A financially successful program that does not produce appropriate clinical outcomes is not sustainable.

Outcome measures may include:

• Wound-area reduction
• Healing rates for appropriately selected wounds
• Major and minor amputation
• Resolution or reduction of radiation-related bleeding
• Graft or flap salvage
• Infection recurrence
• Hospitalizations and emergency visits
• Treatment completion
• Patient-reported function
• Adverse events
• Time to definitive closure or reconstruction

Outcomes should be stratified by indication and patient risk. Combining carbon monoxide poisoning, diabetic foot ulcers, radiation cystitis, and compromised flaps into one general “success rate” produces little useful information.

Clinical outcome tracking also supports payer discussions, physician engagement, accreditation, quality improvement, and community trust.

Key Financial Metrics for a Hyperbaric Program

Hospital leaders should review a focused operating dashboard rather than waiting for an annual profit-and-loss statement.

Useful measures include:

• New qualified referrals per month
• Referral-to-consult conversion
• Consult-to-treatment conversion
• Prior-authorization approval rate
• Treatments per active patient
• Treatments per chamber day
• Chamber utilization
• Cancellation and no-show rate
• Course completion rate
• Net revenue per treatment
• Variable cost per treatment
• Labor cost per treatment
• Contribution margin per treatment
• Denial and write-off rates
• Days in accounts receivable
• Operating margin
• Capital payback progress

Safety and compliance measures should appear on the same dashboard. These may include barotrauma, emergency decompression, glucose-related interruption, prohibited-item interception, equipment downtime, documentation audit results, and treatments continued without measurable benefit.

When a Hospital Hyperbaric Program Is More Likely to Succeed

A stronger financial case generally exists when the hospital has:

• An established wound and limb-preservation service
• Active vascular, podiatric, surgical, and infectious disease programs
• A meaningful population of radiation oncology survivors
• Documented outmigration to external hyperbaric providers
• Adequate hospital outpatient payer contracts
• A realistic concentration of covered indications
• Strong prior-authorization and revenue-cycle support
• Experienced medical and safety leadership
• Enough volume to support safe staffing and chamber utilization
• A commitment to accreditation and clinical outcome measurement

A program may also provide strategic value in a regional referral center that treats emergency indications, even when those cases do not produce predictable outpatient volume. Emergency capability should be evaluated separately because it requires additional staffing, availability, and hospital resources.

Warning Signs of an Unsustainable Business Model

Leadership should reconsider projections that depend on:

• Immediate full chamber utilization
• A large volume of noncovered or investigational indications
• Routine HBOT for uncomplicated surgical wounds
• Minimal medical director or safety oversight
• Understaffing
• Separate billing assumptions that conflict with bundling rules
• No allowance for denials or cancellations
• Referral estimates based only on disease prevalence
• Continuing every patient through a fixed number of sessions regardless of response
• Revenue assumptions based on hospital charges rather than expected collections

A financially responsible program does not need to choose between clinical discipline and profitability. Clinical discipline is what protects profitability.

Patients referred for HBOT often face limb-threatening wounds, delayed radiation injuries, severe infections, or complicated surgical recovery. Their treatment may require weeks of travel and significant personal commitment. A sustainable program respects that burden by offering HBOT only when the indication is appropriate, the treatment plan is coordinated, and progress is measured honestly.

The strongest return comes from a program that earns physician trust, treats the right patients, maintains reliable utilization, prevents avoidable denials, and demonstrates that its financial performance is supported by meaningful clinical care.

A Strategic and Clinical Framework for Building a Safe, Compliant, and Sustainable Hyperbaric Medicine Service

Starting a hospital-based hyperbaric medicine program is not primarily an equipment-purchasing project. It is the development of a specialized clinical service that combines medical decision-making, pressure-vessel operations, oxygen fire safety, engineering controls, physician supervision, emergency preparedness, and payer-specific documentation.

The strongest programs begin by defining the patients they intend to serve, the clinical capabilities they can support, and the outcomes they expect to improve. Chamber selection, construction, staffing, and financial planning should follow that clinical strategy.

Hyperbaric chambers are FDA-regulated Class II medical devices. The FDA advises facilities to follow each device’s instructions for use, maintain staff training, monitor patients throughout treatment, perform required maintenance and safety checks, and implement strict fire-prevention controls. (U.S. Food and Drug Administration)

Define the Clinical Scope Before Selecting a Chamber

Hospital leadership should first determine whether the program will function primarily as an outpatient wound and radiation-injury service, an emergency hyperbaric referral center, or a broader hospital-based program capable of treating critically ill patients.

A planned clinical scope may include:

• Advanced diabetic lower-extremity wounds
• Delayed radiation tissue injury
• Chronic refractory osteomyelitis
• Compromised grafts and flaps
• Carbon monoxide poisoning
• Arterial gas embolism
• Decompression illness
• Necrotizing soft tissue infections
• Crush injuries and acute traumatic ischemia

These conditions do not create equivalent operational requirements. A program treating stable outpatients during business hours requires a different staffing, chamber, and emergency model from a center accepting intubated patients, emergency transfers, or time-sensitive diving injuries.

The Medicare National Coverage Determination for HBOT identifies specific covered conditions and describes HBOT as adjunctive treatment for several of them. Medicare does not cover every proposed use of hyperbaric oxygen, and coverage requirements may include disease severity, failure of standard care, or continued documentation of improvement. (Centers for Medicare & Medicaid Services)

The hospital should define clearly:

• Which indications will be accepted
• Whether inpatient and outpatient treatment will be available
• Whether emergency referrals will be accepted
• The maximum level of patient acuity
• Whether ventilated or hemodynamically unstable patients can be treated
• Which specialties will share responsibility for patient management
• When patients must be transferred to another hyperbaric center

A program should not advertise emergency or critical-care capability unless staffing, equipment, chamber access, and hospital support can reliably provide that level of service.

Establish Medical and Administrative Governance

A hospital hyperbaric service requires clear clinical ownership. Leadership should identify a qualified hyperbaric medical director early in the planning process rather than waiting until the chamber is installed.

The medical director should help establish:

• Clinical indications and exclusion criteria
• Physician credentialing and privileging requirements
• Treatment protocols
• Emergency procedures
• Patient-screening standards
• Quality metrics
• Peer review and utilization review
• Relationships with referring specialties

The Undersea and Hyperbaric Medical Society publishes current guidance for credentialing, privileging, and supervision of physicians and other clinicians involved in HBOT. UHMS guidance supports formal training, appropriate proctored experience, and privileges that reflect the provider’s education and demonstrated competence. (UHMS)

Administrative governance should include representatives from:

• Hospital medical leadership
• Nursing
• Respiratory therapy
• Facilities and engineering
• Fire and life safety
• Infection prevention
• Risk management
• Pharmacy
• Finance and revenue cycle
• Emergency medicine
• Surgery and critical care
• Wound care
• Compliance and legal services

This group should remain involved through design, construction, commissioning, and clinical launch. Hyperbaric medicine crosses too many operational boundaries to be developed successfully by one department working in isolation.

Complete a Realistic Market and Referral Analysis

A feasibility assessment should be based on identifiable referral volume, not general assumptions about the prevalence of chronic wounds.

The hospital should evaluate:

• Current inpatient and outpatient cases that may meet recognized indications
• Radiation oncology survivorship volume
• Diabetic foot and limb-preservation referrals
• Vascular, podiatric, orthopedic, colorectal, urologic, and head-and-neck surgery volume
• Existing wound-center activity
• Regional trauma and emergency referral patterns
• Competing hyperbaric centers
• Travel distance for patients
• Payer mix and authorization requirements

Claims data alone may overstate demand. A patient with a diabetic foot ulcer, for example, does not automatically qualify for HBOT. Medicare coverage requires a diabetes-related lower-extremity wound classified as Wagner grade III or higher, failure of at least 30 days of standard wound therapy, and continued use of comprehensive wound care. (Centers for Medicare & Medicaid Services)

The volume model should account for the number of treatments per patient, chamber occupancy, cancellation rates, staffing ratios, emergency capacity, preventive maintenance, and the time required for patient preparation and turnover.

A program that requires consistently unrealistic chamber utilization to break even is not financially resilient.

Choose Between Monoplace and Multiplace Capability

Monoplace chambers generally treat one patient at a time. The patient is commonly surrounded by an oxygen-rich chamber atmosphere while clinical personnel remain outside.

Multiplace chambers can accommodate multiple patients and may allow trained personnel to remain inside. The chamber is usually pressurized with air while oxygen is delivered through a mask, hood, or airway circuit.

Neither design is inherently more therapeutic. Chamber selection should reflect the intended patient population and operational model.

Monoplace systems may be appropriate when the program expects:

• Primarily stable outpatients
• Individualized treatment scheduling
• Several simultaneous but independently controlled treatments
• Limited need for direct bedside intervention under pressure
• A lower initial construction footprint than a large multiplace installation
• Multiplace capability may be advantageous when the program expects:
• Critically ill or ventilated patients
• Pediatric patients requiring an attendant
• Patients who need direct clinical assistance
• Multiple patients with compatible treatment profiles
• Emergency diving or gas-embolism referrals
• Complex in-chamber monitoring or intervention

The chamber decision should include an assessment of lifecycle costs, staffing, oxygen and compressed-air infrastructure, maintenance, redundancy, evacuation, emergency access, and future service expansion.

Only FDA-cleared devices should be considered for their cleared intended use. FDA-cleared full-body hyperbaric chambers can be identified under product code CBF, and facilities should review the specific clearance, operating limits, accessories, and manufacturer instructions for each proposed system. (U.S. Food and Drug Administration)

Involve Engineering and Code Authorities Early

Hyperbaric construction should begin with a multidisciplinary design review involving the chamber manufacturer, hospital engineering, architects, mechanical and electrical engineers, fire protection specialists, infection prevention, clinical users, and the authority having jurisdiction.

NFPA 99 contains specific provisions for the design and operation of hyperbaric facilities in Chapter 14. The edition legally adopted by a state or local jurisdiction may differ, so the project team must verify the applicable code with the relevant authority. FDA safety resources also identify NFPA 99 and ASME PVHO-1 as central references for hyperbaric facilities and pressure vessels for human occupancy. (NFPA)

Facility planning may need to address:

• Chamber location and structural loading
• Oxygen and compressed-air supplies
• Ventilation and exhaust
• Electrical classification and grounding
• Fire detection and suppression
• Emergency power
• Patient and equipment egress
• Stretcher and wheelchair access
• Control panels and visibility
• Medical gas alarms
• Environmental monitoring
• Storage of approved supplies
• Separation from ignition sources
• Access for preventive maintenance

The design should also reflect actual patient flow. A critically ill patient should not require transport through congested public areas. An outpatient with limited mobility should have safe access to changing areas, restrooms, glucose testing, wound assessment, and emergency care.

Equipment placement should allow staff to observe patients continuously and respond without unnecessary delay.

Build a Qualified Hyperbaric Team

A hospital hyperbaric program requires more than a physician and a chamber operator. Staffing should reflect the chamber configuration, patient acuity, treatment volume, and services offered.

The core team may include:

• Hyperbaric medical director
• Credentialed hyperbaric physicians
• Registered nurses
• Hyperbaric technologists
• Respiratory therapists
• Wound-care clinicians
• Hyperbaric safety director or coordinator
• Program manager
• Biomedical and facilities support
• Revenue-cycle and authorization staff

Programs treating unstable or ventilated patients may also require support from critical care, anesthesia, emergency medicine, surgery, pharmacy, and respiratory therapy.

UHMS recommends using formal hyperbaric operations and credentialing guidance to determine appropriate staffing and qualifications. Staffing decisions should account for patient acuity, chamber type, team experience, emergency responsibilities, and the ability to respond safely when more than one patient is under pressure. (UHMS)

Training should include:

• Hyperbaric physiology and gas laws
• Patient selection and contraindications
• Ear and sinus pressure management
• Oxygen toxicity recognition
• Chamber operation
• Fire prevention
• Approved and prohibited materials
• Emergency decompression
• Cardiac and respiratory emergencies
• Glucose management
• Equipment compatibility
• Infection prevention
• Patient transfer and evacuation

Staff competency should be verified through direct observation, simulation, written assessment, and documented retraining. Attendance at an educational course does not, by itself, establish operational competence.

Appoint a Hyperbaric Safety Director

The hyperbaric safety director or coordinator should be appointed during planning, not after the program opens.

This role typically oversees:

• Fire-safety policies
• Product and equipment risk assessment
• Chamber-compatible materials
• Preventive maintenance coordination
• Safety training
• Emergency drills
• Incident and near-miss review
• Regulatory and code compliance
• Changes to equipment or clinical practice
• Contractor and vendor access

UHMS accreditation guidance evaluates the qualifications and responsibilities of the hyperbaric safety function. UHMS also recommends specialized safety education and sufficient operational experience for those responsible for this role. (UHMS)

The safety director should have meaningful authority. A program is not safe when the designated safety professional can identify a hazard but lacks the authority to stop a treatment, reject an item, or remove equipment from service.

Create a Comprehensive Fire-Safety System

Oxygen does not ignite independently, but it allows combustible materials to ignite more easily and burn with greater intensity. Fire prevention must therefore be embedded into every stage of treatment.

The FDA’s August 25, 2025 safety communication emphasizes:

• Following manufacturer instructions
• Using proper grounding
• Maintaining staff training
• Monitoring and supervising patients
• Following cleaning and maintenance schedules
• Controlling electrical and static-producing items
• Using hyperbaric-compatible clothing
• Maintaining fire-prevention procedures (U.S. Food and Drug Administration)

The program should develop a formal approval process for every item entering the chamber environment, including:

• Patient clothing and linens
• Wound dressings
• Skin products
• Catheters and tubing
• Monitoring devices
• Prostheses and implants
• Infusion equipment
• Batteries and electronics
• Cleaning products
• Emergency supplies

An item used routinely elsewhere in the hospital is not automatically safe under pressure or in an oxygen-enriched environment.

The hospital should also conduct drills for chamber fire, external fire, power failure, gas-supply failure, communication loss, patient seizure, cardiac arrest, respiratory deterioration, and emergency evacuation.

Develop Standardized Clinical Pathways

Each accepted diagnosis should have a written clinical pathway that defines:

• Referral requirements
• Diagnostic criteria
• Required records
• Standard-care prerequisites
• Contraindication screening
• Treatment protocol
• Monitoring requirements
• Reassessment intervals
• Discontinuation criteria
• Coordination with the referring specialist

A diabetic wound pathway, for example, should confirm vascular assessment, offloading, debridement, infection treatment, glucose management, nutritional support, wound measurement, and failure of standard care when required. CMS specifically states that HBOT must supplement, not replace, these measures. (Centers for Medicare & Medicaid Services)

A radiation-injury pathway should include confirmation of prior radiation exposure, evaluation for recurrent malignancy, organ-specific specialist assessment, and documentation of conventional treatment.

Emergency pathways should define how surgery, resuscitation, antibiotics, critical care, and HBOT will be sequenced. Chamber treatment must not delay a time-critical operation or another definitive intervention.

Build Reimbursement and Documentation Processes Before Launch

Revenue-cycle planning should occur before the first patient is scheduled.

The hospital should create payer-specific matrices for:

• Covered diagnoses
• Prior authorization
• Required wound classifications
• Standard-care documentation
• Physician supervision
• Treatment units
• Continued-coverage requirements
• Medical-necessity appeals
• Inpatient versus outpatient billing

CMS treats HBOT as a physician and hospital outpatient service and limits national Medicare coverage to listed indications. HBOT for diabetic lower-extremity wounds requires continued wound evaluation, and treatment is not covered when measurable healing is not demonstrated during a 30-day treatment period. (Centers for Medicare & Medicaid Services)

Documentation should establish:

• The qualifying diagnosis
• Why HBOT is medically necessary
• Treatments already attempted
• Relevant imaging, cultures, operative findings, or radiation records
• The prescribed pressure and oxygen exposure
• Patient assessment before and after each session
• Adverse events or treatment modifications
• Objective response to therapy
• Continued coordination with standard care

The program should audit documentation before launch using test cases. Discovering a documentation gap after claims are denied is expensive and may expose the hospital to compliance risk.

Commission the Facility Before Treating Patients

Installation does not mean the program is ready for clinical use.

Commissioning should verify:

• Chamber installation and manufacturer acceptance
• Medical gas function
• Pressure controls and alarms
• Communications
• Grounding
• Fire protection
• Emergency power
• Environmental systems
• Preventive maintenance schedules
• Equipment compatibility
• Staff competency
• Emergency response
• Documentation systems
• Medication and supply workflows

The team should perform simulated treatments using realistic scenarios. These exercises should include stable outpatients, nonambulatory patients, glucose abnormalities, ear pain, anxiety, oxygen-delivery failure, seizure, cardiac symptoms, and emergency decompression.

Problems identified during simulation should be corrected before patient treatment begins.

Pursue Hyperbaric Facility Accreditation

UHMS accreditation evaluates the adequacy of a facility’s equipment, staffing, training, policies, safety systems, and quality of patient care. Accreditation is voluntary in many settings, but it provides an external review specifically designed for clinical hyperbaric operations. (UHMS)

Accreditation readiness should be incorporated from the beginning. Designing policies, staffing, records, and physical space around recognized standards is more efficient than attempting to rebuild the program after it is operational.

The hospital should conduct a formal gap analysis before opening and repeat it before an accreditation survey.

Measure Clinical Quality and Operational Performance

A hyperbaric program should be evaluated by more than chamber occupancy and revenue.

Useful quality measures may include:

• Treatment completion rates
• Ear and sinus barotrauma
• Oxygen-toxicity events
• Glucose-related interruptions
• Emergency decompressions
• Fire-safety variances
• Prohibited-item interceptions
• Equipment failures
• Wound-healing progress
• Limb preservation
• Resolution of radiation-related bleeding
• Graft or flap salvage
• Hospitalizations and emergency visits
• Patient-reported function
• Documentation and authorization denials

Near misses should be reviewed even when no injury occurs. A prohibited item found before compression, an incorrect treatment profile caught during the safety pause, or an equipment alarm detected during setup can reveal weaknesses in the system.

The quality process should include regular case review, treatment-utilization review, policy updates, staff education, and documented corrective actions.

Common Mistakes When Starting a Hospital Hyperbaric Program

Several planning errors can weaken an otherwise promising service:

• Purchasing chambers before defining the clinical model
• Building the business plan around noncovered or poorly supported indications
• Treating the program as an extension of wound care rather than a separate specialty service
• Underestimating fire-safety and engineering requirements
• Delaying recruitment of the medical director and safety director
• Assuming existing hospital equipment is chamber compatible
• Advertising emergency capability without sustainable staffing
• Failing to integrate vascular, surgical, infectious disease, radiation oncology, and critical-care services
• Opening before emergency drills and competency validation are complete
• Measuring success primarily through treatment volume

A successful hospital hyperbaric program is a clinical system supported by specialized equipment, not an equipment service searching for patients.

The hospital should be able to explain why the program is needed, which patients it will treat, how those patients will be protected, how outcomes will be measured, and how the service will integrate with the rest of the organization. When those questions are answered before construction begins, the program is far more likely to provide safe, clinically appropriate, and sustainable care.

When Hyperbaric Oxygen Therapy May Support Compromised Incisions, Grafts, Flaps, and Complex Postoperative Wounds

Most surgical wounds heal without hyperbaric oxygen therapy. When blood supply is adequate, the incision is mechanically stable, infection is controlled, and the patient has sufficient physiologic reserve, the body can progress through inflammation, tissue formation, and remodeling using standard postoperative care.

Some wounds do not follow this expected course. An incision may separate, a skin flap may become ischemic, irradiated tissue may fail to heal, or infection may increase local oxygen demand while damaging the microcirculation. These complications can place tissue, reconstruction, function, and sometimes the patient’s life at risk.

Hyperbaric oxygen therapy, commonly abbreviated as HBOT, may be considered when a surgical wound is compromised by a recognized hypoxic, ischemic, infectious, or radiation-related condition. It is not a routine recovery treatment for every operation, and it does not replace surgical correction of the problem causing the wound to fail.

How Surgical Wounds Normally Heal

Surgical wound healing is a coordinated process involving clot formation, inflammation, new tissue production, collagen deposition, wound contraction, epithelial coverage, and gradual remodeling.

Immediately after surgery, platelets and clotting factors help control bleeding and establish a temporary wound matrix. Inflammatory cells then remove damaged tissue and microorganisms. Fibroblasts begin producing extracellular matrix and collagen, while endothelial cells support the development of new capillaries. Epithelial cells migrate across the surface, and the wound gradually gains tensile strength.

Healing depends on several conditions:

• Adequate arterial inflow and microvascular perfusion
• Sufficient oxygen delivery
• Mechanical stability and appropriate wound closure
• Control of bacterial burden and infection
• Removal of devitalized tissue
• Adequate protein, calories, vitamins, and minerals
• Appropriate glucose management
• Control of edema and excessive pressure
• Management of tobacco exposure and other systemic risks

Standard wound care aims to support rapid healing without infection or other complications while restoring the best possible function and appearance. (ACS)

Oxygen is essential throughout this process. It supports cellular energy production, collagen maturation, angiogenesis, epithelial activity, and oxygen-dependent microbial killing by leukocytes. When perfusion falls or edema increases the distance between capillaries and cells, tissue oxygen tension may become inadequate even when systemic oxygen saturation is normal.

Why a Surgical Wound May Fail to Heal

A nonhealing surgical wound is a clinical finding, not a diagnosis. The team must determine why healing has slowed or stopped before adding an adjunctive treatment.

Common causes include:

• Inadequate arterial blood flow
• Venous congestion
• Excessive tension on the incision
• Hematoma or seroma
• Surgical site infection
• Retained foreign material
• Devitalized tissue
• Radiation-associated vascular damage
• Pressure, shear, or repeated trauma
• Uncontrolled edema
• Poor glucose control
• Malnutrition
• Tobacco or nicotine exposure
• Immunosuppressive medications
• An unrecognized fistula, abscess, or deeper structural problem

A wound may also separate because the fascia, muscle, subcutaneous tissue, or skin did not gain sufficient strength before mechanical stress was applied. Superficial skin separation is clinically different from deep fascial dehiscence, which may require urgent surgical intervention.

New or worsening pain, swelling, erythema, heat, purulent drainage, fever, tissue discoloration, malodor, or an incision that begins opening should prompt clinical evaluation. The CDC notes that new or worsening pain outside the expected postoperative pattern may be relevant to surgical site infection assessment. (CDC)

HBOT should not be used to obscure these warning signs or postpone evaluation by the operating surgeon.

How HBOT Changes Oxygen Delivery

During HBOT, the patient breathes oxygen while exposed to increased atmospheric pressure inside a medical hyperbaric chamber. Increased pressure raises arterial oxygen tension and substantially increases the amount of oxygen dissolved directly in plasma.

The resulting oxygen-rich plasma can move through functioning vessels and create a stronger diffusion gradient into hypoxic tissue. Oxygen may reach viable cells located farther from a capillary than it could under ordinary atmospheric conditions.

In a compromised surgical wound, this may support:

• Cellular energy production in hypoxic but viable tissue
• Fibroblast activity and collagen formation
• Angiogenic signaling
• Epithelial migration
• Leukocyte oxidative microbial killing
• Edema reduction through hyperoxic vasoconstriction
• Modulation of ischemia-reperfusion injury
• Survival of threatened graft or flap tissue

These effects require at least some functioning circulation. HBOT cannot deliver oxygen effectively to tissue that has no blood supply, and it cannot revive tissue that is already irreversibly necrotic.

A major arterial obstruction, twisted flap pedicle, constricting hematoma, thrombosed anastomosis, undrained abscess, or unstable wound closure requires direct correction. Oxygen therapy may support viable tissue after that correction, but it is not a substitute for it.

HBOT Is Not Recommended for Routine Postoperative Recovery

HBOT is neither necessary nor recommended for a normal, uncompromised surgical incision, skin graft, or flap. The Undersea and Hyperbaric Medical Society specifically distinguishes threatened grafts and flaps from reconstructions that are healing normally. (UHMS)

The evidence for using HBOT broadly across acute surgical wounds is limited. A Cochrane review found no high-quality evidence establishing routine benefit for acute surgical wound healing. Two small studies suggested possible benefits in skin grafting and trauma, but both had important risks of bias. (PubMed)

This means a patient should not receive HBOT simply because they recently underwent surgery, want to heal faster, or are concerned about the appearance of a scar. Routine use adds cost, treatment burden, and medical risk without a clearly established benefit.

A clinically appropriate referral should identify a specific wound-threatening process that HBOT can plausibly address.

Compromised Skin Grafts and Surgical Flaps

The clearest surgical wound application involves a compromised graft or flap.

A skin graft depends initially on close contact with a vascular wound bed. Fluid accumulation, infection, movement, inadequate recipient-site perfusion, or poor tissue preparation can interfere with graft survival.

A flap carries its own blood supply, but that circulation can become compromised by arterial insufficiency, venous congestion, thrombosis, kinking, compression, excessive tension, or damage to the vascular pedicle. Free flaps may develop problems at the microsurgical arterial or venous anastomosis.

Warning findings may include:

• Increasing pallor or cyanosis
• Cool tissue
• Delayed capillary refill
• Progressive edema
• Dark or congested appearance
• Loss of Doppler signal
• Poor bleeding after pinprick
• Epidermolysis or tissue necrosis

Suspected vascular compromise requires immediate evaluation by the reconstructive surgeon. A hematoma may need evacuation, a tight dressing may need removal, and a thrombosed pedicle may require urgent return to the operating room.

HBOT may be added after correctable mechanical or vascular causes have been addressed. Its goal is to maximize survival of hypoxic but viable tissue and potentially reduce the extent of flap loss, regrafting, or repeat reconstruction. (UHMS)

Medicare covers HBOT for the preparation and preservation of compromised skin grafts, while explicitly stating that this coverage is not for the primary management of wounds. (Centers for Medicare & Medicaid Services)

Wounds in Previously Irradiated Tissue

Surgical wounds within a previous radiation field may heal poorly because radiation can progressively damage the small blood vessels supplying skin, muscle, mucosa, and bone.

Irradiated tissue may become hypovascular, fibrotic, and chronically hypoxic. Surgery introduces additional metabolic demand into tissue that may have little reserve. The incision can separate, soft tissue may break down, and exposed bone or hardware may become difficult to cover.

HBOT may be considered when the surgical problem meets the recognized indication of delayed radiation injury, including soft tissue radionecrosis or osteoradionecrosis. It may be delivered as part of treatment for an existing wound or coordinated with debridement and reconstruction in selected patients.

The treatment objective is to increase oxygenation and stimulate vascular remodeling in viable irradiated tissue. HBOT does not eliminate the need to exclude recurrent cancer, remove necrotic tissue, manage infection, or perform appropriate reconstruction. Medicare recognizes soft tissue radionecrosis and osteoradionecrosis as covered indications when HBOT is used alongside conventional treatment. (Centers for Medicare & Medicaid Services)

Surgical Wounds Complicated by Infection

A surgical site infection can involve the skin and subcutaneous tissue, the deeper incision, or an organ or space entered during surgery. Infection increases local oxygen demand while inflammatory edema, thrombosis, and tissue destruction impair oxygen delivery.

HBOT is not routinely indicated for an uncomplicated postoperative infection. Standard treatment may include:

• Opening or draining the wound
• Obtaining appropriate cultures
• Debridement of devitalized tissue
• Removal of infected material when necessary
• Targeted antimicrobial therapy
• Management of sepsis
• Delayed closure or reconstruction

HBOT may become relevant when the infection falls within a recognized hyperbaric indication, such as necrotizing fasciitis, gas gangrene, chronic refractory osteomyelitis, or a sufficiently advanced diabetic lower-extremity wound.

These are specific clinical conditions, not interchangeable labels for any infected incision. CMS lists progressive necrotizing infections, gas gangrene, chronic refractory osteomyelitis, and qualifying diabetic wounds among covered indications. (Centers for Medicare & Medicaid Services)

Even in these settings, source control remains essential. An undrained abscess, infected implant, necrotic fascia, or sequestrum cannot be treated adequately with oxygen alone.

Wound Dehiscence and Tissue Necrosis

Wound dehiscence occurs when the edges or deeper layers of a surgical wound separate. The clinical significance depends on which tissue layers are involved and why the failure occurred.

A small superficial opening may be managed with local wound care or secondary-intention healing. Deep fascial separation, exposure of an implant, bowel evisceration, or rapidly expanding tissue necrosis may require urgent surgery.

Before considering HBOT, the team should determine whether dehiscence is being driven by:

• Infection
• Ischemia
• Excessive tension
• Hematoma or fluid collection
• Fascial failure
• Radiation damage
• Nutritional or metabolic impairment
• Repeated pressure or motion
• Medication-related suppression of healing

HBOT may support selected hypoxic wounds after the structural problem has been addressed, particularly when compromised flaps, radiation injury, severe ischemia, or another recognized indication is present.

It should not be described as a general treatment for every incision that opens. The clinical target is tissue hypoxia within a salvageable wound, not dehiscence as an isolated visual finding.

Standard Surgical Wound Care Must Continue

HBOT works best when it is added to a coordinated wound and surgical plan.

The plan may include:

• Surgical debridement
• Vascular assessment and revascularization
• Drainage of hematoma, seroma, or abscess
• Culture-directed antimicrobial therapy
• Pressure redistribution
• Negative-pressure wound therapy
• Moisture-balanced dressings
• Glucose management
• Nutritional optimization
• Tobacco and nicotine cessation
• Flap revision or reconstructive surgery

A wound that remains ischemic, infected, mechanically unstable, or exposed to repeated pressure is unlikely to heal simply because oxygen exposure has been increased.

CMS applies this principle explicitly to qualifying diabetic lower-extremity wounds. HBOT must be delivered in addition to standard wound care, which includes vascular evaluation, nutritional and glucose optimization, debridement, moist wound management, offloading, and treatment of infection. (Centers for Medicare & Medicaid Services)

The same clinical reasoning applies more broadly to complicated surgical wounds, even when the specific coverage pathway differs.

Which Surgical Patients May Merit a Hyperbaric Evaluation?

A referral may be reasonable when a postoperative wound involves a recognized hyperbaric indication or a clearly threatened reconstruction.

Potential referral scenarios include:

• A compromised skin graft or flap after correctable mechanical causes have been addressed
• A surgical wound within significantly irradiated tissue
• Progressive necrotizing soft tissue infection after urgent debridement
• Chronic refractory osteomyelitis associated with a surgical site
• Acute traumatic ischemia following limb reconstruction
• A qualifying advanced diabetic lower-extremity wound after surgery
• Threatened replanted or revascularized tissue
• Selected complex wounds with documented hypoxia and limited reconstructive options

The referral should include the operative history, wound chronology, vascular findings, infection evaluation, imaging, pathology, microbiology, previous reconstruction, and the specific clinical objective for HBOT.

The question should not be, “Will oxygen help healing?” Oxygen is involved in nearly every healing process. The more useful question is, “Is this wound failing because of a hypoxic condition that HBOT can address, after the correctable surgical problems have been treated?”

What an HBOT Course May Involve

The protocol depends on the indication, urgency, tissue response, and timing of surgery.

Compromised grafts and flaps are often treated urgently because salvageable tissue may deteriorate quickly. Treatment may be delivered more than once per day during the initial period, followed by a reduced schedule as perfusion and tissue viability improve.

Delayed radiation injury and chronic problem wounds generally require a longer course, often involving weekday treatments over several weeks. Pressure, oxygen duration, air breaks, and the total number of sessions are prescribed by the hyperbaric physician.

During treatment, the team may monitor:

• Wound dimensions
• Tissue color and temperature
• Capillary refill
• Doppler signals
• Graft or flap viability
• Drainage and infection findings
• Granulation and epithelialization
• Need for further debridement
• Progress toward closure or reconstruction
• Patient tolerance and adverse effects

A predetermined number of treatments should not replace clinical reassessment. Progressive necrosis, new infection, loss of vascular signal, worsening dehiscence, or systemic deterioration requires renewed surgical evaluation.

Measuring Meaningful Clinical Benefit

The objective of HBOT should be defined before treatment begins.

Depending on the wound, meaningful benefit may include:

• Preservation of a compromised flap or graft
• Reduction in the amount of tissue requiring debridement
• Improved granulation over exposed structures
• Progress toward definitive closure
• Reduced wound depth or surface area
• Successful healing within irradiated tissue
• Fewer repeat reconstructive operations
• Preservation of limb or function
• Control of a qualifying infection alongside standard treatment

Photography, wound measurement, perfusion testing, operative findings, and patient-reported function can help document response.

Scar appearance alone is generally not an appropriate indication. HBOT should not be marketed as a routine cosmetic method for producing a finer postoperative scar when the incision is otherwise healing normally.

Current Evidence Requires Careful Patient Selection

Evidence is strongest when HBOT is used for established indications and selected threatened tissue. Evidence is weaker for generic postoperative wound delay, routine cosmetic recovery, and uncomplicated incisions.

Reviews of acute surgical wounds have repeatedly noted a lack of sufficiently large, high-quality randomized trials. Some small studies and observational reports describe improved healing in selected wound complications, but differences in surgical procedures, patient selection, timing, and treatment protocols limit broad conclusions. (PubMed)

This uncertainty makes disciplined selection important. HBOT should be used because the patient has a plausible oxygen-responsive condition and a defined salvage or healing objective, not merely because the wound is difficult.

Risks and Treatment Burden

HBOT is generally well tolerated in appropriately screened patients, but it has recognized risks.

Potential adverse effects include:

• Middle-ear or sinus barotrauma
• Claustrophobia or confinement anxiety
• Temporary myopic vision changes
• Blood glucose instability
• Pulmonary oxygen effects
• Rare oxygen-induced seizure

An untreated pneumothorax is generally considered an absolute contraindication. Pulmonary disease, difficulty equalizing ear pressure, unstable heart failure, seizure risk, medication concerns, and implanted devices require individualized assessment. Pressure-related barotrauma and oxygen-related neurologic, pulmonary, and ophthalmologic effects are the principal categories of hyperbaric complications. (NCBI)

The treatment course may also require daily travel while the patient continues dressing changes, surgical appointments, antibiotics, rehabilitation, or home health care. The expected benefit should justify this burden.

Coordinating HBOT with the Surgical Team

Hyperbaric treatment should remain integrated with the surgeon’s plan. The operating surgeon understands the reconstruction, tissue planes, implants, closure tension, and consequences of additional debridement. The wound and hyperbaric teams contribute assessment of oxygenation, infection, tissue viability, and treatment response.

Strong communication is particularly important when decisions are time sensitive. A threatened flap may require immediate operative revision. A necrotizing infection may require another debridement. A wound in irradiated tissue may need staged reconstruction. Chamber scheduling must accommodate these priorities rather than compete with them.

For appropriately selected patients, HBOT may improve the environment in which healing occurs. It can increase oxygen delivery to compromised tissue, support angiogenesis and immune function, and help preserve selected grafts, flaps, or surgical wounds.

Its value depends on using it for the right wound, at the right time, with the structural, vascular, infectious, and metabolic causes of failure addressed simultaneously.

The Clinical Role of Hyperbaric Oxygen Alongside Emergency Surgery, Antibiotics, and Critical Care

Necrotizing fasciitis is a rapidly progressive infection that destroys fascia, subcutaneous tissue, and surrounding structures. Although the skin may initially show limited changes, extensive injury can already be developing beneath the surface. The infection can progress quickly to septic shock, organ failure, limb loss, and death.

Immediate surgical debridement and broad-spectrum antimicrobial therapy remain the foundations of treatment. Hyperbaric oxygen therapy, or HBOT, may be added at appropriately equipped medical centers, but it must never delay operative exploration, resuscitation, antibiotic administration, or another necessary debridement.

The Undersea and Hyperbaric Medical Society recognizes necrotizing soft tissue infections as an accepted indication for adjunctive HBOT. Infectious disease guidance is more cautious because randomized clinical trial evidence has not established a definitive benefit. The practical point shared across these perspectives is that HBOT can only be considered after the essential surgical and critical care priorities have been protected. (UHMS)

Recognizing Necrotizing Fasciitis as a Surgical Emergency

Necrotizing fasciitis can begin after surgery, trauma, a puncture wound, an injection, an ulcer, or another break in the skin. It can also follow blunt trauma without an obvious open wound. Diabetes, cancer, kidney disease, cirrhosis, immune suppression, and vascular disease may increase risk, but the infection can occur in people without a major preexisting condition. (CDC)

Early findings may resemble cellulitis or a routine postoperative infection. Warning signs include:

• Severe pain that appears disproportionate to visible skin changes
• Rapid progression of redness, warmth, swelling, or tenderness
• Pain extending beyond the visibly affected area
• Firm or wooden-feeling subcutaneous tissue
• Bullae, ecchymosis, skin discoloration, or necrosis
• Crepitus or gas within the tissue
• Fever, hypotension, confusion, or other systemic toxicity
• Failure to improve with treatment for presumed cellulitis

Pain may become less prominent as superficial nerves are destroyed, so a decrease in pain does not always indicate improvement. The CDC emphasizes that severe pain, rapidly spreading inflammation, and fever require immediate medical attention, particularly after an injury or operation. (CDC)

Laboratory testing and imaging may support the diagnosis, but neither should postpone surgery when clinical suspicion is high. CT or MRI may demonstrate fascial thickening, fluid, gas, or deep tissue involvement, yet the definitive diagnosis is often made during operative exploration.

Risk-scoring systems can help organize clinical information, but they are not sufficiently reliable to exclude necrotizing fasciitis in a patient with concerning symptoms. Clinical deterioration should outweigh a reassuring score.

Immediate Surgical Debridement Remains the Priority

Necrotizing fasciitis cannot be treated successfully with oxygen or antibiotics alone. Infected and devitalized fascia has poor blood flow, which limits antimicrobial delivery and allows bacterial toxins and inflammatory injury to continue.

The patient requires prompt surgical consultation and operative exploration. IDSA guidance recommends immediate surgical involvement when an aggressive soft tissue infection is associated with systemic toxicity or suspicion of necrotizing fasciitis or gas gangrene. (IDSA)

Surgical treatment may include:

• Wide exposure of the involved fascial planes
• Excision of necrotic skin, subcutaneous tissue, fascia, and muscle
• Drainage of fluid collections
• Removal of infected foreign material
• Fasciotomy when compartment pressure is present
• Amputation when tissue cannot be preserved safely
• Collection of deep tissue for microbiology and pathology

The first operation is often only the beginning of source control. Patients commonly require repeated exploration because tissue that appeared viable initially may later declare itself nonviable. The surgical team must continue debridement until no advancing necrosis or infected tissue remains.

HBOT should be scheduled around operative care. A chamber session should never take priority over an indicated return to surgery.

Broad-Spectrum Antibiotics Should Begin Promptly

Empiric antimicrobial treatment should begin as soon as necrotizing fasciitis is suspected. Therapy must initially cover a broad range of possible organisms because the infection may be polymicrobial or caused by a single aggressive pathogen.

IDSA recommends broad empiric coverage such as an anti-MRSA agent combined with therapy active against gram-negative and anaerobic organisms. When group A streptococcal necrotizing fasciitis is documented, penicillin plus clindamycin is recommended. Clindamycin is commonly included because it suppresses bacterial protein and toxin production in addition to its antimicrobial activity. (IDSA)

Potential pathogens include:

• Group A Streptococcus
• Staphylococcus aureus, including MRSA
• Enteric gram-negative organisms
• Anaerobic bacteria
• Clostridial species
• Marine organisms such as Vibrio vulnificus
• Mixed aerobic and anaerobic flora

Antibiotic therapy should be narrowed when operative cultures, blood cultures, Gram stain findings, and susceptibility testing provide reliable microbiologic information.

A superficial wound culture may not accurately represent organisms deep within the fascia. Operative tissue and fluid specimens are generally more useful for directing definitive treatment.

Critical Care Supports the Patient Through Systemic Illness

Necrotizing fasciitis frequently produces sepsis, shock, acute kidney injury, respiratory failure, coagulopathy, and severe metabolic disturbances. Patients may need intensive care before and after each operation.

Supportive management may include:

• Intravenous fluid resuscitation
• Vasopressor therapy
• Mechanical ventilation
• Renal replacement therapy
• Blood products
• Electrolyte and glucose management
• Nutritional support
• Analgesia and sedation
• Thromboembolism prevention
• Treatment of underlying cardiac, pulmonary, or renal disease

HBOT does not replace any of these interventions. A center considering chamber treatment must be able to maintain the patient’s airway, infusions, monitoring, and hemodynamic support under pressure.

How HBOT May Affect Necrotizing Fasciitis

Necrotizing infections create severe local tissue hypoxia. Edema, vascular thrombosis, endothelial injury, inflammatory activity, and increased metabolic demand reduce oxygen delivery at the same time the immune system requires oxygen to control infection.

During HBOT, the patient breathes oxygen while exposed to increased atmospheric pressure. This substantially raises arterial oxygen tension and increases the amount of oxygen dissolved directly in plasma.

The oxygen-rich plasma can reach functioning microvessels surrounding the infected area and create a stronger diffusion gradient into hypoxic but viable tissue. Potentially relevant effects include:

• Increased oxygen tension in threatened tissue
• Improved oxygen-dependent leukocyte microbial killing
• Inhibition of selected anaerobic organisms
• Suppression of clostridial toxin production
• Support for the activity of certain antimicrobial agents
• Reduction of edema through hyperoxic vasoconstriction
• Modulation of leukocyte adhesion and inflammatory signaling
• Support for viable tissue surrounding the debrided wound

HBOT cannot oxygenate tissue that has no functional circulation, and it cannot restore tissue that is already necrotic. Its potential value lies primarily in supporting the viable tissue surrounding the infection while surgery and antibiotics eliminate the source. (PLOS)

Hyperbaric Oxygen and Bacterial Toxin Activity

The biologic rationale for HBOT has historically been particularly strong in clostridial infections. Clostridial organisms thrive in low-oxygen environments and can produce toxins that cause rapid muscle destruction, hemolysis, vascular injury, and systemic collapse.

Elevated tissue oxygen tensions may inhibit anaerobic bacterial growth and suppress production of certain toxins. HBOT may therefore reduce continued tissue injury while surgery removes devitalized tissue and antibiotics control the organism.

Necrotizing fasciitis is not always anaerobic or clostridial. Many infections involve group A streptococci, staphylococci, gram-negative organisms, or mixed flora. Proposed HBOT benefits in these cases relate more to host immune function, tissue oxygenation, edema control, and inflammatory modulation than to a direct antibacterial effect.

HBOT Must Follow, Not Delay, Source Control

The most important operational rule is that HBOT must not delay surgery.

A reasonable treatment sequence may include:

1. Immediate assessment, cultures, resuscitation, and broad-spectrum antibiotics.
2. Urgent operative exploration and radical debridement.
3. Postoperative stabilization in intensive care.
4. HBOT when it can be delivered safely and without delaying another operation.
5. Repeated surgical reassessment and debridement as required.
6. Continued antimicrobial and critical care management.

IDSA does not recommend HBOT for clostridial gas gangrene because benefit has not been proven and transfer or chamber treatment could delay resuscitation and surgical debridement. Hyperbaric organizations support HBOT when it is readily available and integrated without weakening those priorities. (IDSA)

These positions highlight the importance of local capability. HBOT may be more practical at a hospital with an on-site chamber, intensive care staffing, surgical services, and chamber-compatible life-support equipment. Transferring an unstable patient away from immediate operative care solely to obtain HBOT may create more risk than benefit.

Which Patients May Be Considered for HBOT?

There is no single laboratory value, wound appearance, or organism that establishes a mandatory need for HBOT.

A hyperbaric consultation may be considered when:

• Necrotizing infection has been confirmed or is strongly suspected
• Initial surgical source control has been completed
• Repeat surgery remains immediately available
• Extensive viable tissue remains at risk
• Severe local hypoxia, edema, or microvascular compromise is present
• Clostridial or another anaerobic infection is suspected
• The patient can be monitored safely under pressure
• An appropriately staffed medical hyperbaric chamber is available
• Chamber treatment will not delay surgery, antibiotics, or resuscitation

The patient’s stability matters. Severe shock, an uncontrolled airway, active hemorrhage, or an untreated pneumothorax may make immediate chamber treatment unsafe.

Critically ill or mechanically ventilated patients can be treated in selected hospital-based hyperbaric facilities, particularly multiplace chambers with trained inside attendants. This requires chamber-compatible ventilators, infusion systems, monitoring equipment, and staff experienced in hyperbaric critical care.

What an HBOT Protocol May Involve

Treatment protocols vary according to infection severity, suspected organisms, surgical findings, patient stability, and facility practice.

Hyperbaric medical organizations have described early, relatively intensive treatment during the period of active progression. Some protocols provide multiple sessions during the first 24 to 72 hours, followed by additional treatments according to infection control and tissue response. A 2025 prospective observational study noted that hyperbaric recommendations commonly involve early treatment, with twice-daily sessions during the initial period and more intensive treatment when gas gangrene is suspected. (Springer Link)

A chamber treatment may involve pressure in the range of approximately 2.0 to 3.0 atmospheres absolute, oxygen-breathing periods, and scheduled air breaks. No single pressure, duration, or number of treatments has been proven optimal for every patient.

Treatment planning must account for:

• Timing of repeat operative exploration
• Mechanical ventilation and airway security
• Vasopressor and infusion requirements
• Chest tubes and pulmonary injury
• Glucose management
• Wound dressings and drains
• Chamber-compatible equipment
• Communication and emergency decompression procedures

HBOT should be discontinued or postponed when it interferes with a more urgent intervention. Progressive necrosis during a treatment course requires surgical reassessment, not simply another oxygen exposure.

Current Evidence for HBOT in Necrotizing Fasciitis

The evidence remains encouraging but uncertain. Randomized controlled trials have not established that HBOT causes a reduction in mortality, amputation, or organ failure. Most published evidence comes from retrospective studies, registries, cohort studies, and meta-analyses of observational data. (Springer Link)

A 2024 analysis of 60,481 surgically treated U.S. hospital admissions found that fewer than 1 percent received HBOT. After statistical adjustment, HBOT was associated with lower in-hospital mortality and lower amputation risk. However, the database did not provide the timing, pressure, number, or duration of hyperbaric treatments, and its retrospective design could not eliminate selection bias. (PLOS)

A 2025 Scandinavian prospective observational study included 405 patients, 325 of whom received HBOT. Thirty-day mortality was 7 percent in the treated group and 43 percent in the untreated group. The investigators emphasized that patients receiving HBOT were less acutely ill at baseline, creating substantial selection bias. They concluded that the association was promising but did not establish causation and that a randomized trial remains necessary. (Springer Link)

This distinction is essential. Observational studies repeatedly associate HBOT with improved survival, but they cannot prove that HBOT itself produced the difference. Centers capable of delivering HBOT may also have greater experience, faster surgical access, specialized critical care, or different referral patterns.

HBOT should therefore be described as a biologically plausible and clinically accepted adjunct at some centers, not as a proven replacement for standard treatment or a guaranteed method of improving survival.

Risks of HBOT in Critically Ill Patients

Potential hyperbaric complications include:

• Middle-ear or sinus barotrauma
• Pulmonary pressure injury
• Temporary vision changes
• Blood glucose instability
• Oxygen toxicity
• Rare oxygen-induced seizure
• Device malfunction under pressure
• Interruption of critical care during transport or chamber treatment

An untreated pneumothorax is generally considered an absolute contraindication. Chest trauma, pulmonary air trapping, seizure risk, implanted devices, and unstable cardiovascular disease require individual assessment.

The most significant practical risk may be disruption of essential care. Moving a patient between the operating room, intensive care unit, and hyperbaric chamber requires coordinated staff, equipment, and contingency planning. A medical center should not provide HBOT for necrotizing fasciitis unless it can maintain the same standard of critical care inside and around the chamber.

Wound Reconstruction and Recovery After Infection Control

Survival from necrotizing fasciitis often requires extensive removal of skin, fascia, muscle, or an extremity. After the infection is controlled, patients may face a prolonged period of wound management and reconstruction.

Ongoing care may include:

• Additional debridement
• Negative-pressure wound therapy
• Skin grafting
• Local or free-flap reconstruction
• Ostomy or urinary diversion care
• Physical and occupational therapy
• Prosthetic rehabilitation
• Pain and scar management
• Nutritional rehabilitation
• Psychological support

HBOT may support threatened tissue during the acute infection, but it does not eliminate the physical and emotional consequences of extensive surgery.

Patients and families may have little time to process rapidly changing decisions about debridement, amputation, organ support, and survival. Clear communication is part of appropriate care. The clinical team should explain that aggressive surgery is not a sign that treatment has failed. It is often the intervention that makes survival possible.

HBOT may be incorporated when the facility can deliver it promptly and safely without compromising source control. Its role is to support, not replace, the combined efforts of surgery, infectious disease treatment, intensive care, wound reconstruction, and rehabilitation.

Clinical Planning for Extractions, Implants, Healing, and Osteoradionecrosis Risk After Head and Neck Radiation

Dental surgery after head and neck radiation requires more planning than the same procedure in nonirradiated tissue. Radiation may reduce vascular density, alter bone remodeling, increase fibrosis, and weaken the ability of oral tissues to recover from trauma. An extraction socket or implant osteotomy that would ordinarily heal without difficulty can become a persistent wound within a heavily irradiated region.

The principal concern is osteoradionecrosis, commonly abbreviated as ORN. This condition involves devitalized irradiated bone and may present with exposed bone, pain, infection, drainage, fistula formation, impaired oral function, or pathologic fracture.

The goal is not to deny necessary dental care to cancer survivors. An infected or painful tooth can create its own significant risks. The clinical objective is to determine whether surgery is truly necessary, understand the radiation exposure at the proposed site, reduce avoidable tissue injury, and follow the patient until healing is clearly established.

Why Irradiated Jawbone Heals Differently

Radiation can injure the endothelial cells lining the small blood vessels that supply bone and adjacent soft tissue. Over time, progressive vascular loss, fibrosis, and changes in cellular activity may leave the tissue less capable of responding to infection or surgical trauma.

Normal extraction healing depends on blood-clot formation, inflammatory cell activity, development of granulation tissue, mucosal coverage, and gradual remodeling of the socket. These processes require adequate vascularity, oxygen delivery, immune function, and viable bone.

Within an irradiated field, several parts of this sequence may be impaired:

• Fewer functional blood vessels may reach the surgical site.
• Fibrotic tissue may be less elastic and more difficult to mobilize.
• Salivary dysfunction may increase caries and periodontal disease.
• Bone turnover and remodeling may be altered.
• Infection may be harder to control within poorly perfused tissue.
• Mucosal breakdown may expose vulnerable bone.

The 2024 joint guideline from the International Society of Oral Oncology, Multinational Association of Supportive Care in Cancer, and American Society of Clinical Oncology considers jaw sites exposed to at least 50 Gy to be at increased risk for ORN. It also identifies dentoalveolar surgery, poor oral hygiene, and tobacco use as important risk factors. (OMS Group)

Radiation Dose and Osteoradionecrosis Risk Assessment

A history of head and neck radiation does not provide enough information to estimate surgical risk. The total cancer-treatment dose may differ substantially from the dose delivered to a specific extraction or implant site.

Before finalizing the dental treatment plan, the clinical team should review the original radiation plan whenever it is available. The review should identify:

• The dose delivered to the proposed surgical site
• Whether the mandible, maxilla, or both were exposed
• The volume of bone that received 50 Gy or more
• The relationship between the tooth and the high-dose region
• The radiation technique and completion date
• Previous surgery or ORN within the same field

Current guidance strongly recommends reviewing the dose delivered to the mandible and maxilla before planning dental treatment in a patient with previous head and neck radiation. (OMS Group)

The mandible is generally of particular concern because its anatomy and vascular supply may leave portions of the bone more vulnerable to radiation injury. Risk is still site specific. An anterior mandibular tooth outside the high-dose field may present a different clinical problem from a posterior mandibular molar located within a region that received a substantial dose.

Time since radiation should also be documented, but no elapsed interval makes previously irradiated bone completely equivalent to nonirradiated bone. ORN can develop years after treatment, particularly when surgery, infection, trauma, or severe dental disease challenges the tissue’s limited healing reserve. The history should therefore remain part of lifelong dental planning.

Evaluating the Tooth and Surrounding Bone

The decision to operate should begin with a diagnosis, not simply with the observation that a tooth has a poor appearance.

The examination may include:

• Dental and cancer-treatment history
• Assessment of pain, swelling, drainage, and mobility
• Periodontal probing
• Evaluation of mucosal integrity
• Sensory examination when nerve symptoms are present
• Periapical or panoramic radiographs
• Cone-beam CT or conventional CT when anatomy or bone disease requires further definition
• Review of previous ORN, delayed healing, or reconstructive surgery

Clinicians should look for evidence that ORN may already be present. Exposed bone, a nonhealing socket, a mucosal or cutaneous fistula, unexplained radiographic sclerosis or lysis, and bone that can be probed through a periodontal defect may indicate existing disease rather than uncomplicated dental pathology. The current guideline defines ORN using clinical and radiographic findings within an anatomic site previously exposed to therapeutic head and neck radiation.

When ORN is suspected, the patient may require evaluation by oral and maxillofacial surgery, head and neck surgery, dental oncology, or another experienced specialist before the tooth is removed. Recurrent malignancy must also remain in the differential diagnosis when findings are atypical, progressive, or accompanied by a suspicious mass.

Alternatives to Dental Extraction After Radiation

Preserving a treatable tooth may avoid surgical injury to irradiated bone. Current guidance recommends offering alternatives to extraction for teeth in high-risk areas unless recurrent infection, uncontrolled pain, or another problem cannot be resolved conservatively. (OMS Group)

Depending on the tooth and clinical circumstances, alternatives may include:

• Root canal therapy
• Restorative treatment
• Crown modification
• Periodontal treatment
• Removal of a traumatic cusp or sharp edge
• Decoronation or another limited intervention
• Continued surveillance of a stable, asymptomatic condition

Conservative treatment should not become indefinite postponement of necessary source control. A nonrestorable tooth with recurrent abscesses, cellulitis, uncontrolled pain, or progressive infection can threaten surrounding tissue and the patient’s general health.

The decision should balance two risks: the risk of surgical injury to irradiated bone and the risk of allowing active dental disease to continue.

Planning Dental Extractions in Irradiated Bone

When extraction is necessary, the procedure should be completed by a clinician who understands the patient’s radiation history and ORN risk. Referral to an oral and maxillofacial surgeon or dental oncologist is often appropriate for high-dose sites, complex teeth, previous healing problems, or patients with established radiation injury.

The operative objective is to remove the dental source of disease while producing as little additional injury as reasonably possible. The surgical plan may consider:

• The least traumatic method of tooth removal
• Whether sectioning the tooth can limit force on the surrounding bone
• The minimum bone removal necessary for safe extraction
• Management of sharp or clearly nonviable bone
• Preservation of periosteal and soft-tissue blood supply
• Whether mucosal coverage can be obtained without excessive tension
• The need for biopsy or microbiologic sampling
• Management of anticoagulant or antiplatelet therapy
• Postoperative nutrition and oral hygiene

There is no single extraction technique proven to prevent ORN in every patient. Procedure design should reflect the tooth, anatomic site, radiation dose, soft-tissue condition, and the surgeon’s ability to achieve stable healing without creating additional trauma.

A painful or infected tooth should not be treated as an elective cosmetic issue. Patients often arrive after months of discomfort because they were told that extraction was impossible after radiation. In many cases, necessary surgery can still be performed, but it requires risk-adapted planning rather than a blanket refusal.

Antibiotics and Antiseptic Mouth Rinses

The 2024 ISOO-MASCC-ASCO guideline recommends considering oral antibiotics before and after invasive dental procedures in patients at higher risk because the treatment site lies within an irradiated portion of the mandible or maxilla. The evidence quality is low, so antibiotic selection and duration should be individualized rather than applied as one universal regimen. (OMS Group)

Antibiotics do not restore vascularity and should not be expected to compensate for retained infection, traumatic surgery, or inadequate follow-up. Their role is to reduce perioperative bacterial burden when the anticipated risk justifies their use.

For patients whose extraction site shows delayed healing, the guideline allows antiseptic rinses such as chlorhexidine or povidone-iodine to be used at least twice daily until adequate healing is confirmed. The patient should remain under close dental or surgical observation rather than relying on a rinse while exposed bone or infection progresses. (OMS Group)

Antimicrobial products should be selected with attention to allergies, local protocols, renal function, medication interactions, microbial findings, and the presence of active infection.

Pentoxifylline and Tocopherol Around Dental Surgery

Pentoxifylline and tocopherol, commonly called the PENTO regimen, have been studied as a strategy for modifying radiation-associated fibrosis and supporting healing.

The 2024 guideline gives a weak recommendation for considering pentoxifylline 400 mg twice daily and tocopherol 1,000 IU once daily in cancer-free patients undergoing invasive dental procedures at sites that received at least 50 Gy. The suggested period is at least one week before the procedure and four weeks afterward, preferably until the socket has healed. (OMS Group)

This is not a universal protocol and should not be self-initiated. The evidence is based primarily on observational studies rather than randomized trials. Pentoxifylline and high-dose tocopherol may be inappropriate in patients with increased bleeding risk or certain renal, cardiac, hepatic, or medication-related concerns. The guideline specifically emphasizes evaluating contraindications before prescribing the regimen. (OMS Group)

The prescribing clinician should coordinate with the surgeon and the patient’s medical team, particularly when anticoagulants, antiplatelet agents, cardiovascular disease, renal impairment, or active cancer are present.

Dental Implants in Irradiated Bone

Dental implants can improve mastication, speech, prosthetic stability, and quality of life after head and neck cancer treatment. Implant placement also creates a surgical osteotomy within irradiated bone and therefore requires careful risk assessment.

Current guidance recommends avoiding implants in high-risk ORN zones unless less invasive methods of restoring oral function are not feasible. (OMS Group)

Implant planning should consider:

• Radiation dose and dose distribution
• Mandibular versus maxillary location
• Bone volume and quality
• Soft-tissue condition
• Salivary dysfunction
• Periodontal and oral hygiene status
• Tobacco exposure
• Previous reconstructive surgery
• Prior ORN
• Ability to maintain long-term implant care

Implant survival and freedom from ORN are different outcomes. An implant may integrate successfully while the surrounding tissue remains vulnerable to later breakdown. Patients require long-term hygiene, prosthetic maintenance, and surveillance for peri-implant inflammation, exposed bone, pain, or drainage.

When HBOT May Be Considered Before Dental Surgery

Hyperbaric oxygen therapy has historically been used before and after dental extraction in irradiated bone. Traditional protocols were intended to increase tissue oxygenation and stimulate angiogenesis before surgery.

Routine prophylactic HBOT is no longer recommended for every patient undergoing dental extraction after head and neck radiation. The 2024 ISOO-MASCC-ASCO guideline concluded that available evidence shows limited preventive benefit. It allows that HBOT may still be offered selectively when a substantial volume of the planned surgical site received more than 50 Gy. (OMS Group)

The HOPON randomized trial studied patients undergoing extraction or implant placement in a mandible exposed to more than 50 Gy. ORN occurred in 6.4 percent of the HBOT group and 5.7 percent of the control group, which did not demonstrate a routine preventive advantage from HBOT. All participants also received perioperative antibiotics and chlorhexidine. (PubMed)

A selective hyperbaric consultation may still be reasonable when the patient has several high-risk features, such as:

• A substantial volume of bone exposed to a high radiation dose
• Previous ORN or a markedly delayed extraction-site healing history
• Poor-quality soft tissue over the planned surgical site
• Extensive surgery rather than a straightforward extraction
• Limited reconstructive options if healing fails
• Multiple local and systemic healing risks
• A procedure in which even limited tissue loss would have major functional consequences

The expected benefit should be defined before treatment begins. HBOT should not be presented as a guarantee against ORN or used to compensate for untreated infection, incomplete surgery, or inadequate follow-up.

Postoperative Healing Surveillance

Follow-up should continue until mucosal closure and stable healing are clearly established. A patient should not be considered healed simply because pain has improved or the immediate postoperative period was uneventful.

Clinicians should monitor for:

• Persistent socket exposure
• Increasing pain or swelling
• Purulent drainage
• Foul taste or odor
• Mucosal or facial fistula formation
• Numbness or altered sensation
• Loosening of nearby teeth
• Progressive radiographic change
• Pathologic fracture symptoms

Delayed healing should prompt reassessment of infection, retained bone or root fragments, radiation dose, oral hygiene, tobacco exposure, nutritional status, glucose control, prosthetic trauma, and possible ORN.

Current guidance recommends close clinical and radiographic surveillance when ORN is suspected or when abnormalities are detected.

Early specialist assessment is preferable to repeated short antibiotic courses without establishing why the socket remains open. Antibiotics may suppress a secondary infection while necrotic bone continues to progress underneath the mucosa.

Coordinated Care Protects Oral Function

Dental surgery in irradiated bone is safest when the dentist, oral surgeon, radiation oncologist, head and neck team, and hyperbaric physician communicate directly.

The radiation oncologist can provide site-specific dose information. The dental team can determine whether the tooth is salvageable. The surgeon can design the least disruptive effective procedure. The medical team can manage anticoagulation, diabetes, nutrition, tobacco dependence, and other systemic risks. A hyperbaric consultation can be added when the site and procedure create a credible need for adjunctive oxygen therapy.

For the patient, the plan should be understandable. They should know why surgery is necessary, how radiation affects healing, what steps are being taken to reduce risk, and which symptoms require prompt evaluation.

The presence of irradiated bone changes the treatment plan, but it does not eliminate the possibility of appropriate dental care. Careful dosimetric review, conservative treatment when feasible, risk-adapted surgery, and documented healing surveillance allow clinicians to address painful or infected teeth while reducing the likelihood of preventable complications.

Current Evidence, Patient Selection, and Dental Risk Reduction After Head and Neck Radiation

Osteoradionecrosis, commonly abbreviated as ORN, is a serious late complication of radiation therapy involving the jaw. It occurs when irradiated bone becomes devitalized and loses the ability to heal normally. Patients may develop exposed bone, persistent pain, infection, drainage, fistulas, difficulty eating, or pathologic fracture.

Hyperbaric oxygen therapy, or HBOT, has historically been used before and after dental extractions to reduce the risk of ORN. That practice remains familiar within hyperbaric and oral surgery communities, but the evidence has changed. Current multidisciplinary guidance does not recommend routine prophylactic HBOT for every patient who needs dental surgery after head and neck radiation. Instead, prevention begins with dental care before radiation, lifelong oral disease control, review of the radiation dose delivered to the jaw, and careful planning of any invasive procedure. (OMS Group)

What Is Osteoradionecrosis of the Jaw?

ORN is generally characterized by necrotic jawbone within an area previously exposed to therapeutic radiation, without recurrent cancer directly explaining the bone abnormality. It may appear as visibly exposed bone, bone that can be probed through a periodontal pocket or fistula, or a radiographic area of lytic or sclerotic change.

Radiation affects bone, soft tissue, and the small blood vessels that support them. Progressive vascular injury, fibrosis, cellular depletion, and impaired remodeling can leave the jaw less capable of recovering from infection, trauma, or surgery. A dental extraction that would normally heal uneventfully may therefore result in a persistent socket, exposed bone, infection, or progressive necrosis within a heavily irradiated area. (UHMS)

The mandible is affected more often than the maxilla because of differences in anatomy, blood supply, bone density, and the radiation dose received during treatment. The clinical consequences may range from a small area of exposed bone to extensive mandibular destruction requiring segmental resection and microvascular reconstruction.

Which Patients Are at Higher Risk for Osteoradionecrosis?

Risk is not determined by a history of head and neck radiation alone. The location and dose of radiation, the condition of the teeth, the proposed procedure, and the patient’s broader health all matter.

The 2024 ISOO-MASCC-ASCO guideline considers patients whose mandible or maxilla received at least 50 Gy to be at increased risk. The guideline also identifies poor oral hygiene, dentoalveolar surgery, and tobacco use as important modifiable risk factors.

Risk assessment should consider:

• The radiation dose delivered to the proposed surgical site
• The volume of mandible or maxilla included in the radiation field
• Time since radiation therapy
• Existing periodontal or periapical disease
• Previous dental extractions or oral surgery
• Xerostomia and radiation-related caries
• Tobacco and alcohol exposure
• Diabetes, nutritional status, and immune function
• Prior ORN or delayed healing
• The complexity and traumatic potential of the planned procedure

A radiation oncologist’s treatment plan can be more informative than the total prescribed cancer dose. A patient may have received a high overall dose while the proposed extraction site received substantially less. Conversely, a tooth may lie within a region of the mandible that received a dose associated with meaningful lifetime risk. Current guidance recommends reviewing the original radiation plan before finalizing dental treatment after head and neck radiation.

Prevention Begins Before Radiation Therapy

The most reliable opportunity to reduce ORN risk occurs before radiation begins. Patients receiving therapeutic radiation that may involve the jaws should undergo a comprehensive dental, periodontal, and radiographic assessment as early as possible. The dental team should receive information about the planned treatment field, anticipated jaw dose, and expected radiation start date. (OMS Group)

Teeth with active infection or a poor long-term prognosis may be removed before radiation, particularly when they are expected to lie within a high-dose field. When clinically possible, current guidance advises allowing approximately two weeks of healing between extraction and radiation. Cancer treatment should not be dangerously delayed solely to achieve a preferred dental healing interval.

Prevention also includes:

• Daily prescription-strength topical fluoride when indicated
• Management of periodontal disease and caries
• Treatment of ill-fitting dentures and traumatic appliances
• Smoking cessation
• Education about lifelong ORN risk
• Regular dental surveillance after cancer treatment
• Early management of xerostomia and oral infection

Modern radiation planning techniques can also reduce risk by limiting the mean dose to the jaw and the volume of bone receiving more than 50 Gy when tumor coverage permits.

Why Prophylactic HBOT Was Historically Used

The traditional prophylactic approach was developed from the concept that irradiated tissue becomes hypovascular, hypocellular, and hypoxic. By substantially increasing tissue oxygen tension, repeated hyperbaric exposures were intended to stimulate angiogenesis, improve fibroblast function, and strengthen the healing environment before surgery.

A widely recognized historical protocol used 20 HBOT sessions before an extraction or other invasive dental procedure, followed by 10 sessions after surgery. This became known as the 20/10 protocol. (PubMed Central (PMC))

The biologic rationale remains plausible. HBOT increases dissolved plasma oxygen and temporarily elevates oxygen availability in tissue supplied by functioning vessels. Repeated exposures may support vascular and connective-tissue responses within selected delayed radiation injuries. However, a credible mechanism does not establish that every irradiated patient receives a meaningful preventive benefit. (PubMed)

What Current Evidence Says About Routine Prophylactic HBOT

The strongest modern trial evaluating prevention is the HOPON study. It enrolled patients requiring dental extractions or implant placement in mandibular regions that had received more than 50 Gy. Participants received antibiotics and chlorhexidine, while the intervention group also completed 30 HBOT sessions at 2.4 ATA. (PubMed Central (PMC))

A total of 144 patients were randomized, with 100 included in the primary analysis. At six months, ORN occurred in 6.4 percent of patients assigned to HBOT and 5.7 percent of controls. The study did not demonstrate a preventive advantage for routine HBOT, although the overall event rate was lower than historically expected and the hyperbaric group reported fewer acute symptoms. (PubMed)

Based on the available evidence, the 2024 ISOO-MASCC-ASCO guideline states that routine prophylactic HBOT before dental extractions is not recommended. This was a weak recommendation based on low-quality evidence, reflecting both the absence of demonstrated routine benefit and continuing uncertainty in narrowly defined high-risk circumstances. (ASCOPubs)

This is an important distinction. Current evidence does not show that HBOT is ineffective in every patient. It shows that applying a lengthy hyperbaric protocol to all previously irradiated patients undergoing extraction is not supported.

When Prophylactic HBOT May Still Be Considered

Current guidance allows that prophylactic HBOT may be offered selectively when an invasive procedure will involve a site where a substantial volume of the mandible or maxilla received more than 50 Gy. The decision should be individualized rather than based on radiation history alone.

A selective hyperbaric consultation may be reasonable when several high-risk features are present, such as:

• A very high dose to the proposed surgical site
• Previous ORN in the same or adjacent area
• A history of markedly delayed healing
• Extensive surgery rather than a simple extraction
• Poor soft-tissue quality within the radiation field
• Limited reconstructive options if healing fails
• Multiple interacting medical or local risk factors
• A procedure involving a particularly vulnerable mandibular region

The consultation should include the oral or maxillofacial surgeon, radiation oncologist, dental specialist, and hyperbaric physician. The team should define the anticipated benefit, available alternatives, planned surgical technique, and consequences if healing does not occur.

HBOT should not be presented as a guarantee against ORN. Even after prophylactic treatment, patients still require careful surgery, infection control, oral hygiene, and close follow-up.

Planning Dental Extractions After Head and Neck Radiation

Whenever possible, clinicians should consider alternatives to extraction in high-risk regions. Endodontic therapy, restoration, crown modification, or symptom-directed management may preserve a tooth without exposing irradiated bone. Dental implants in high-risk regions also require careful assessment because implant placement creates a surgical injury within the jaw.

When extraction is unavoidable, the procedure should be planned using the least traumatic approach that will accomplish the clinical objective. Excessive periosteal stripping, unnecessary bone removal, and poorly controlled soft-tissue injury may further compromise the healing environment.

Current guidance supports considering perioperative antibiotics for higher-risk patients and antiseptic mouth rinses when socket healing is delayed. It also gives a weak, low-evidence recommendation for pentoxifylline and tocopherol around invasive dental procedures in selected patients exposed to at least 50 Gy at the treatment site, provided there are no contraindications such as increased bleeding risk. These measures require individualized prescribing and should not be started without oversight from the treating team.

Primary soft-tissue closure may be appropriate when it can be achieved without excessive tension or additional tissue disruption. The patient should be monitored until mucosal healing is complete rather than discharged from follow-up after a brief symptom-free period.

What a Prophylactic HBOT Course May Involve

When HBOT is selected, the precise protocol is prescribed by the hyperbaric physician in coordination with the surgical team.

Historical protocols commonly involved treatment before and after the dental procedure. The HOPON trial used 30 daily hyperbaric exposures, delivering 100 percent oxygen at 2.4 ATA for approximately 80 to 90 minutes. (PubMed Central (PMC))

A clinical course may include:

1. Hyperbaric medical evaluation and risk screening.
2. Review of radiation dosimetry and the planned dental procedure.
3. Preoperative HBOT sessions.
4. Atraumatic dental surgery with appropriate infection-control measures.
5. Postoperative HBOT when included in the selected protocol.
6. Continued oral surgery follow-up until the socket or surgical site has healed.

An untreated pneumothorax is generally considered an absolute contraindication to HBOT. Ear or sinus equalization problems, pulmonary disease, unstable heart failure, seizure risk, blood glucose management, medications, and implanted devices require patient-specific assessment.

Risks and Practical Burden of Prophylactic HBOT

HBOT is generally well tolerated in appropriately screened patients, but it is not risk free. Potential adverse effects include middle-ear or sinus barotrauma, temporary myopic vision changes, claustrophobia, pulmonary oxygen effects, blood glucose changes, and rare oxygen-induced seizure.

Prophylaxis also creates a substantial logistical burden. A patient may need to attend treatment five days per week, complete sessions before surgery, coordinate the dental procedure within a specific timeframe, and return for additional postoperative treatments.

Transportation, work, caregiving responsibilities, treatment fatigue, mobility, and insurance coverage can all influence whether the plan is realistic. These burdens matter when the expected absolute reduction in risk is uncertain.

The preventive decision should therefore compare the patient’s individualized ORN risk against the medical, practical, and financial costs of treatment.

Recognizing Early Signs of Osteoradionecrosis

Prevention does not end when the extraction is completed. Patients and clinicians should monitor for:

• A socket that does not progressively close
• Exposed or palpable bone
• Persistent pain or swelling
• Purulent drainage
• Bad taste or odor
• Numbness or altered sensation
• A nonhealing oral or facial fistula
• Increasing difficulty opening the mouth
• Unexplained loosening of adjacent teeth

These findings require evaluation rather than repeated empiric treatment without diagnosis. Assessment may include direct oral examination, periodontal evaluation, panoramic imaging, cone-beam CT, conventional CT, or MRI depending on the presentation. Recurrent malignancy must remain part of the differential diagnosis when findings are atypical or progressive. (OMS Group)

HBOT used to prevent ORN should also be distinguished from HBOT considered after ORN has developed. Established disease may require antimicrobial therapy, local wound care, medical antifibrotic treatment, debridement, resection, or vascularized reconstruction. Current guidance considers HBOT with surgery an option in selected cancer-free patients, but evidence for treating established jaw ORN also remains limited.

A Multidisciplinary Approach to ORN Prevention

The most effective preventive strategy is not a single procedure. It is a coordinated pathway that begins before radiation and continues throughout survivorship.

Radiation oncologists should minimize avoidable jaw exposure without compromising tumor treatment. Dental specialists should eliminate active disease and educate patients before radiation. General dentists should provide lifelong preventive care and recognize that invasive procedures may require specialist review. Oral surgeons should obtain radiation-dose information and plan procedures according to the specific anatomic risk. Hyperbaric physicians should reserve HBOT for cases in which the expected benefit is clinically credible and clearly defined.

Current evidence does not support routine prophylactic HBOT for every dental extraction after head and neck radiation. It supports thoughtful selection. For a patient with limited jaw exposure and a straightforward procedure, careful dental surgery and follow-up may be sufficient. For a patient with heavily irradiated mandibular bone, previous healing failure, and a high-consequence surgical site, multidisciplinary discussion of HBOT may still be appropriate.

The objective is not simply to complete an extraction without an immediate complication. It is to preserve healthy oral tissue, maintain function, and reduce the lifelong risk of a condition that can profoundly affect nutrition, speech, appearance, comfort, and quality of life.

A Clinical Approach to Bleeding Control, Bladder Evaluation, Patient Selection, and Tissue Repair

Hemorrhagic cystitis is characterized by inflammation and bleeding from the bladder lining. Its severity ranges from microscopic hematuria to persistent gross bleeding with clot retention, urinary obstruction, anemia, transfusion dependence, and hemodynamic instability.

Pelvic radiation is one of the most clinically significant causes of chronic hemorrhagic cystitis. The condition may also occur after exposure to urotoxic chemotherapy, particularly cyclophosphamide or ifosfamide, and after viral reactivation in immunocompromised patients, including those who have undergone hematopoietic stem cell transplantation. The cause matters because hyperbaric oxygen therapy, or HBOT, has its strongest evidence base in delayed radiation-induced hemorrhagic cystitis. Evidence for chemotherapy-associated or viral disease remains more limited and is largely observational. (PubMed Central (PMC))

HBOT should not be viewed as an emergency replacement for bladder drainage, clot evacuation, transfusion, infection treatment, or stabilization. Its primary role is restorative. By improving oxygen delivery to damaged tissue, HBOT may help the bladder develop a healthier microvascular supply and become less vulnerable to recurrent bleeding.

Determining the Cause of Hemorrhagic Cystitis

Hematuria in a patient with a history of cancer treatment should not automatically be attributed to radiation or chemotherapy. Other causes may include urinary tract infection, bladder or upper urinary tract malignancy, recurrent cancer, kidney or bladder stones, renal disease, prostatic bleeding, trauma, recent instrumentation, and medication-associated bleeding.

The clinical assessment should document:

• The onset, frequency, and approximate volume of bleeding
• Passage of clots or difficulty emptying the bladder
• Pelvic pain, dysuria, urgency, or frequency
• Previous pelvic radiation and chemotherapy exposure
• Stem cell or solid-organ transplantation history
• Anticoagulant and antiplatelet use
• Recent urinary procedures
• Fever, immunosuppression, or infection symptoms
• Previous treatments for hemorrhagic cystitis

Laboratory evaluation commonly includes a complete blood count, renal function testing, coagulation studies, urinalysis, and urine culture. Additional infectious testing may be required in immunocompromised patients when BK polyomavirus, adenovirus, or another infectious cause is suspected. (PubMed Central (PMC))

Cystoscopy is important when bleeding is persistent, recurrent, severe, or inadequately explained. It allows direct inspection of the bladder, clot evacuation, treatment of focal bleeding, and evaluation for suspicious lesions. Upper urinary tract imaging may also be appropriate, especially in patients with gross hematuria or risk factors for urinary tract malignancy. (PubMed Central (PMC))

Stabilizing Active Bladder Bleeding

Patients with heavy bleeding, urinary retention, symptomatic anemia, or cardiovascular instability require immediate stabilization. HBOT should not delay interventions needed to restore urinary drainage or control acute blood loss.

Initial management may include:

• Intravenous access and hemodynamic assessment
• Serial hemoglobin measurement
• Fluid resuscitation and blood-product support when indicated
• Correction of a clinically significant coagulopathy
• Placement of a large-bore three-way urinary catheter
• Manual clot irrigation
• Continuous bladder irrigation
• Cystoscopic clot evacuation and fulguration

Persistent or life-threatening bleeding may require intravesical therapies, selective arterial embolization, urinary diversion, or surgery. The most appropriate intervention depends on bleeding severity, bladder integrity, renal function, comorbidities, prior treatments, and the underlying cause. (PubMed Central (PMC))

The presence of significant hematuria does not necessarily exclude HBOT. It does mean that the patient must first be stable enough to tolerate transport, chamber compression, and a series of scheduled treatments.

Why Radiation Causes Recurrent Hemorrhagic Cystitis

Late radiation cystitis is driven by progressive injury to the small blood vessels supplying the bladder wall. Radiation damages vascular endothelial cells and may lead to narrowing, thrombosis, and eventual loss of portions of the microcirculation.

The bladder tissue becomes relatively hypoxic, fibrotic, and less capable of normal repair. The mucosa may become thin and ulcerated, while fragile telangiectatic vessels form within the damaged tissue. These vessels can rupture repeatedly as the bladder fills, empties, or is exposed to minor irritation. (PubMed Central (PMC))

This process explains why focal cauterization may provide incomplete or temporary control. Fulguration can treat an identifiable bleeding vessel, but it does not necessarily correct the broader vascular insufficiency affecting the surrounding bladder.

HBOT is intended to address that underlying tissue environment. It is used within the recognized indication of delayed soft tissue radiation injury rather than as a nonspecific treatment for hematuria. Medicare’s national coverage determination includes soft tissue radionecrosis when HBOT is used as an adjunct to conventional treatment. (Centers for Medicare & Medicaid Services)

How Hyperbaric Oxygen Supports Bladder Tissue Repair

During HBOT, the patient breathes oxygen while exposed to increased atmospheric pressure inside a medical hyperbaric chamber. The elevated oxygen partial pressure substantially increases the amount of oxygen dissolved directly in plasma.

This oxygen-rich plasma can reach functioning vessels near the injured bladder tissue and create a stronger diffusion gradient into chronically hypoxic areas. Repeated exposures may stimulate biologic responses that continue beyond the temporary period of elevated tissue oxygen.

Potential therapeutic effects include:

• Increased oxygen delivery to hypoxic bladder tissue
• Angiogenic signaling and formation of new capillary networks
• Support for fibroblast activity and collagen remodeling
• Improved mucosal and epithelial repair
• Modulation of chronic inflammation
• Greater tissue resistance to recurrent ulceration and bleeding

HBOT is therefore different from an immediate hemostatic procedure. Its purpose is to improve the tissue’s long-term capacity to heal and maintain vascular integrity. Clinical improvement may begin during treatment, but symptom reduction may also continue after the course is completed. (AUANews)

Selecting Patients for Hyperbaric Therapy

HBOT may be considered when hemorrhagic cystitis is associated with delayed radiation injury and symptoms persist or recur after appropriate urologic evaluation and conventional care.

Potential candidates include patients with:

• Recurrent gross hematuria attributed to pelvic radiation
• Diffuse bladder telangiectasia that is difficult to treat focally
• Recurrent bleeding after cystoscopic fulguration
• Radiation-associated bladder ulceration
• Repeated clot-retention episodes
• Iron-deficiency anemia or transfusion requirements
• Persistent urinary urgency, frequency, pain, or dysuria
• A desire to preserve bladder function and avoid more destructive procedures

The Canadian Urological Association recommends considering HBOT relatively early after cystoscopy and fulguration have failed, rather than reserving it only for patients who have undergone every available invasive treatment. (PubMed Central (PMC))

The expected treatment target should be defined before therapy begins. For one patient, success may mean complete resolution of hematuria. For another, it may mean fewer bleeding episodes, elimination of transfusion requirements, fewer hospitalizations, improved urinary function, or avoidance of urinary diversion.

HBOT is less likely to correct symptoms caused primarily by an untreated tumor, severe bladder-neck obstruction, urethral stricture, large stone, fixed fistula, or markedly contracted bladder. These conditions require separate urologic or oncologic management.

HBOT for Non-Radiation Hemorrhagic Cystitis

Chemotherapy-associated hemorrhagic cystitis is frequently linked to cyclophosphamide or ifosfamide. Their metabolite acrolein can injure the bladder lining, particularly when protective measures are inadequate or high-dose therapy is used. Viral hemorrhagic cystitis, especially from BK polyomavirus, is an important complication after allogeneic stem cell transplantation. (PubMed Central (PMC))

Management of these conditions focuses on treating or reducing the underlying cause, maintaining hydration and urinary drainage, controlling pain, managing immunosuppression when appropriate, treating infection when a specific therapy is available, and supporting the patient through bleeding and cytopenias.

HBOT has been used in refractory chemotherapy-related and viral hemorrhagic cystitis, and retrospective studies have reported improvement in selected patients. The available evidence is substantially less mature than the evidence for delayed radiation injury, with small cohorts, heterogeneous populations, and no definitive randomized trials establishing routine use. (PubMed Central (PMC))

A hyperbaric referral in these cases should therefore involve close coordination with hematology, oncology, transplant medicine, infectious disease, and urology. The decision should reflect disease severity, response to conventional treatment, immune status, platelet count, transport safety, and the center’s ability to manage a medically complex patient under pressure.

What a Course of HBOT May Involve

Hyperbaric protocols vary according to the facility, chamber system, medical history, and treatment response. A common radiation cystitis course involves daily treatment, Monday through Friday, for several weeks.

The RICH-ART randomized trial used:

• 30 to 40 treatment sessions
• 100 percent oxygen
• Pressure of 240 to 250 kPa, approximately 2.4 to 2.5 atmospheres absolute
• 80 to 90 minutes of oxygen breathing per session

These parameters provide an evidence-based reference but are not a universal prescription for every patient. The hyperbaric physician selects the pressure, oxygen duration, air breaks, and number of treatments based on clinical circumstances. (PubMed)

A typical visit includes pre-treatment assessment, removal of prohibited items, gradual compression, oxygen exposure at the prescribed pressure, controlled decompression, and post-treatment reassessment.

During the treatment course, clinicians may monitor:

• Frequency and severity of hematuria
• Clot-retention events
• Hemoglobin and iron status
• Transfusion requirements
• Emergency visits and hospitalizations
• Need for irrigation or cystoscopy
• Urinary urgency, frequency, pain, and continence
• Treatment tolerance and adverse effects

The course should remain connected to urologic care. New obstruction, heavy bleeding, fever, declining hemoglobin, or worsening pain requires clinical evaluation rather than simply continuing scheduled chamber sessions.

What the Evidence Shows

A 2024 systematic review and meta-analysis included 556 patients treated with HBOT for radiation-induced hemorrhagic cystitis. Approximately 89.9 percent experienced some degree of symptom improvement, while the pooled complete remission rate for hematuria was 55 percent. The included studies differed in patient severity, treatment protocols, follow-up, and definitions of response, so these results should not be interpreted as a guaranteed individual outcome. (PubMed Central (PMC))

The RICH-ART randomized trial found that HBOT improved patient-reported urinary symptoms compared with standard care. Its five-year follow-up, published in 2025, found that improvement remained clinically meaningful among many initial responders. Of 70 patients included in the long-term analysis, 48, or 68.6 percent, met the study’s responder definition. Some patients received another HBOT course after symptoms recurred. (PubMed)

These findings support HBOT as a meaningful treatment option for selected patients with chronic radiation cystitis. They also show that response is not universal. Some patients improve partially, some relapse, and others ultimately require additional urologic intervention.

Anticoagulation and Bleeding Risk

Many patients with radiation-induced hemorrhagic cystitis also take anticoagulant or antiplatelet medications for atrial fibrillation, coronary artery disease, previous stroke, venous thromboembolism, or vascular disease.

These medications may increase bleeding from fragile irradiated vessels, but they may also be essential for preventing stroke, myocardial infarction, or recurrent thrombosis. They should not be discontinued without direction from the prescribing clinician.

Management may require coordination among urology, cardiology, hematology, primary care, and hyperbaric medicine to determine whether treatment interruption is acceptable, how long it can continue, and when medication should be restarted.

HBOT may improve the health of the bladder tissue, but it does not eliminate the need for an individualized assessment of thrombotic and bleeding risk.

Risks and Contraindications of HBOT

HBOT is generally well tolerated in appropriately screened patients, but it has recognized adverse effects.

Potential complications include:

• Middle-ear or sinus barotrauma
• Temporary myopic vision changes
• Claustrophobia or confinement anxiety
• Blood glucose instability
• Pulmonary oxygen effects
• Rare oxygen-induced seizure

An untreated pneumothorax is generally considered an absolute contraindication. Pulmonary air trapping, difficulty equalizing ear pressure, unstable heart failure, seizure risk, implanted medical devices, and medication concerns require individualized evaluation.

Cancer history is not itself a contraindication. HBOT treats the radiation-damaged bladder tissue, not the underlying malignancy. Appropriate cancer surveillance must continue, particularly when new hematuria, pain, obstruction, or suspicious cystoscopic findings develop.

Integrating HBOT into a Bladder-Preservation Strategy

The management of hemorrhagic cystitis is most effective when it follows a coordinated sequence rather than a disconnected series of procedures.

Immediate priorities are to stabilize the patient, maintain urinary drainage, remove clots, and control clinically significant bleeding. The next step is to identify the cause, exclude malignancy, and address infection, medication effects, obstruction, or other contributing factors.

HBOT becomes most relevant when chronic radiation injury is confirmed and recurrent bleeding reflects diffuse hypoxic tissue rather than one isolated lesion. Its purpose is to improve the condition of the bladder wall, reduce dependence on repeated procedures, and preserve urinary function when possible.

Living with recurrent hematuria can be frightening and exhausting. Patients may avoid travel, work, exercise, or social activities because they fear bleeding, clot retention, or another emergency visit. A clinically successful treatment plan should therefore measure more than whether the urine appears clear on one particular day. It should evaluate whether the patient is experiencing fewer crises, improved function, greater independence, and a meaningful reduction in the burden of disease.

How Hyperbaric Oxygen Therapy May Address Hematuria and Chronic Bladder Injury After Prostate Radiation

Radiation therapy is an established treatment for localized, locally advanced, recurrent, and postoperative prostate cancer. External beam radiation therapy, brachytherapy, and salvage radiation after prostatectomy can provide effective cancer control, but the bladder neck, bladder base, prostatic urethra, and surrounding pelvic tissues may receive radiation during treatment.

Some urinary effects occur during radiation and improve after treatment ends. Radiation cystitis is a delayed complication that may appear months or years later. Patients may develop urinary frequency, urgency, burning, pelvic discomfort, reduced bladder capacity, or blood in the urine. In severe cases, hematuria can produce clots, urinary retention, anemia, transfusion requirements, emergency visits, and repeated urologic procedures.

Hyperbaric oxygen therapy, or HBOT, may be considered when symptoms are caused by delayed radiation injury and persist despite appropriate urologic care. HBOT does not treat prostate cancer itself. Its purpose is to improve the oxygenation and vascular health of previously irradiated bladder tissue.

Why Radiation Cystitis Can Develop Years After Prostate Cancer Treatment

Radiation can damage the endothelial cells that line small blood vessels within the bladder wall. Over time, affected vessels may narrow, thrombose, or disappear. This progressive loss of microvascular supply leaves the tissue chronically hypoxic, less cellular, and less capable of normal repair.

The bladder lining may become thin and fragile. Abnormal telangiectatic vessels can form within the irradiated mucosa and rupture as the bladder fills, empties, or is exposed to minor mechanical stress. Fibrosis may also reduce bladder elasticity and contribute to urgency, frequent urination, pain during filling, and decreased functional capacity.

This delayed process differs from the temporary inflammation that may occur during prostate radiation. Acute urinary symptoms often result from mucosal irritation and swelling. Chronic radiation cystitis reflects a longer-term pattern of vascular injury, hypoxia, fibrosis, and abnormal tissue remodeling.

The delayed timing can be unsettling for patients who completed prostate cancer treatment years earlier. New hematuria may immediately raise concerns about cancer recurrence. Those concerns deserve a complete evaluation rather than an assumption that radiation is the cause. (PubMed Central (PMC))

Hematuria After Prostate Radiation Requires a Urologic Workup

Blood in the urine after prostate cancer treatment should not automatically be attributed to radiation cystitis. Other conditions may produce similar symptoms, including:

• Bladder or upper urinary tract cancer
• Recurrent or persistent prostate cancer
• Urinary tract infection
• Kidney or bladder stones
• Benign prostatic or prostatic urethral bleeding
• Urethral stricture or bladder-neck contracture
• Renal disease
• Recent catheterization or instrumentation
• Anticoagulant or antiplatelet therapy

The evaluation commonly begins with a detailed history, physical examination, urinalysis, urine culture, blood counts, renal function testing, and review of medications. The clinician should determine the severity and duration of bleeding, whether clots are present, whether the patient can empty the bladder, and whether anemia or hemodynamic compromise has developed.

Cystoscopy allows the urologist to inspect the bladder lining, identify characteristic telangiectasia or ulceration, remove clots, treat focal bleeding, and evaluate suspicious lesions. Upper urinary tract imaging may also be needed, particularly in patients with gross hematuria or other risk factors for urinary tract malignancy. Suspicious bladder lesions may require biopsy, although tissue sampling should be planned carefully because irradiated tissue may heal poorly. (PubMed Central (PMC))

Prostate cancer surveillance should continue according to the patient’s oncologic plan. The prostate-specific antigen trend, original cancer characteristics, treatment history, imaging, and clinical findings help determine whether recurrent disease requires further investigation.

Anticoagulation Can Increase the Severity of Bleeding

Many prostate cancer survivors are older adults with atrial fibrillation, coronary artery disease, previous stroke, venous thromboembolism, or other conditions requiring anticoagulant or antiplatelet therapy.

These medications do not necessarily cause the underlying radiation injury, but they can increase the frequency or severity of bleeding from fragile bladder vessels. Medication review is therefore an important part of the evaluation.

Anticoagulation should not be stopped without direction from the prescribing clinician. The risk of continued hematuria must be balanced against the risk of stroke, myocardial infarction, recurrent thrombosis, or another serious cardiovascular event.

When bleeding is clinically significant, urology, cardiology, hematology, primary care, and the prescribing specialist may need to coordinate:

• Whether medication interruption is medically acceptable
• How long an interruption can safely continue
• Whether dose adjustment is appropriate
• Whether an alternative medication is reasonable
• When treatment should be restarted
• Whether correction of another bleeding risk factor is possible

HBOT may improve the condition of the irradiated bladder tissue, but medication management remains individualized and should continue throughout the treatment course.

How HBOT May Help the Radiation-Damaged Bladder

During HBOT, the patient breathes medical oxygen while exposed to increased atmospheric pressure inside a hyperbaric chamber. The increased pressure raises arterial oxygen tension and substantially increases the amount of oxygen dissolved directly in plasma.

This oxygen-rich plasma can reach functioning vessels at the margins of the radiation field and create a stronger diffusion gradient into hypoxic bladder tissue.

Repeated hyperbaric exposures may support:

• Angiogenic signaling and formation of new capillary networks
• Increased tissue oxygenation between treatments
• Fibroblast activity and collagen remodeling
• Repair of the bladder’s epithelial lining
• Improved integrity of damaged blood vessels
• Modulation of chronic inflammatory activity
• Greater resistance to recurrent tissue breakdown

HBOT is therefore different from a procedure intended to cauterize a single bleeding vessel. Cystoscopic fulguration may stop an identifiable bleeding point, while HBOT is intended to improve the broader tissue environment responsible for recurrent bleeding.

This restorative process takes time. Some patients notice reduced hematuria during treatment. Others improve gradually in the weeks or months following the treatment course as vascular remodeling continues. (AUANews)

Severe Hematuria Must Be Stabilized First

HBOT is not an emergency method of removing clots or immediately controlling major blood loss.

A patient with heavy bleeding, urinary obstruction, symptomatic anemia, or hemodynamic instability may require:

• Placement of a large-bore urinary catheter
• Manual clot evacuation
• Continuous bladder irrigation
• Intravenous fluids
• Blood transfusion or iron replacement
• Correction of clinically significant coagulopathy
• Cystoscopic clot evacuation
• Fulguration or coagulation of active bleeding sites
• Hospital admission and close monitoring

Persistent life-threatening bleeding may require intravesical agents, selective arterial embolization, urinary diversion, or surgery. The selected treatment depends on the severity of bleeding, bladder condition, renal function, prior procedures, and the patient’s overall health.

HBOT may begin after the patient is stable enough to attend repeated chamber treatments. It can be incorporated relatively early when bleeding continues or recurs after appropriate cystoscopic management, rather than being reserved only for patients who have exhausted every invasive option. (PubMed Central (PMC))

Which Prostate Cancer Patients May Be Candidates for HBOT?

A hyperbaric evaluation may be appropriate when a patient has documented pelvic radiation exposure and persistent symptoms consistent with delayed bladder radiation injury.

Potential candidates include patients with:

• Recurrent visible hematuria attributed to radiation cystitis
• Bleeding that returns after cystoscopic fulguration
• Diffuse bladder telangiectasia that is difficult to treat focally
• Radiation-associated bladder ulceration
• Repeated clot-retention episodes
• Iron-deficiency anemia or transfusion requirements
• Persistent urgency, frequency, dysuria, or pelvic discomfort
• A desire to preserve bladder function and avoid more destructive treatment
• Concurrent radiation injury involving other pelvic tissues

The hyperbaric physician should review the prostate cancer treatment history, including radiation modality, treatment field, dose when available, date of completion, previous pelvic surgery, and any subsequent cancer therapy.

The evaluation should also address pulmonary and cardiovascular history, ear-pressure equalization, glucose management, seizure risk, implanted devices, current medications, and the patient’s ability to complete a prolonged treatment schedule.

HBOT is less likely to correct symptoms caused primarily by a fixed structural problem, such as a severe urethral stricture, bladder-neck contracture, established fistula, large bladder stone, active tumor, or severely contracted bladder. These conditions may require separate urologic or surgical management.

Prostatectomy and Salvage Radiation Can Create Additional Complexity

Some patients receive radiation after radical prostatectomy because of adverse pathologic findings, a persistently detectable PSA, or biochemical recurrence. These patients may have urinary incontinence, bladder-neck scarring, altered pelvic anatomy, or previous surgical complications before radiation begins.

When hematuria or lower urinary tract symptoms later develop, several treatment-related factors may overlap:

• Radiation cystitis
• Bladder-neck contracture
• Urethral stricture
• Surgical clip or foreign-body complications
• Stress urinary incontinence
• Recurrent malignancy
• Infection or instrumentation-related trauma

A careful urologic evaluation is needed to determine which condition is responsible for each symptom. HBOT may address delayed radiation tissue injury, but it will not mechanically open a stricture or correct sphincter dysfunction.

This distinction helps establish realistic treatment goals. Reduced bleeding may be achievable even when preexisting incontinence or obstruction requires separate treatment.

What an HBOT Course May Involve

Treatment is prescribed by a hyperbaric physician based on the bladder injury, medical history, previous interventions, treatment tolerance, and clinical response.

Many radiation cystitis protocols involve:

• Treatment five days per week
• Approximately 30 to 40 initial sessions
• Pressure between about 2.0 and 2.5 atmospheres absolute
• Approximately 80 to 90 minutes of oxygen breathing at treatment pressure
• Air breaks when included in the prescribed protocol

The RICH-ART randomized trial used 30 to 40 treatments at approximately 2.4 to 2.5 atmospheres absolute, with 80 to 90 minutes of oxygen exposure per session. (PubMed)

A typical treatment visit includes a clinical assessment, removal of prohibited items, gradual chamber compression, oxygen exposure at the prescribed pressure, controlled decompression, and post-treatment assessment.

Patients may be treated in a monoplace or multiplace chamber. The clinical dose, safety systems, staff competency, and ability to monitor the patient are more important than the chamber configuration.

Blood Glucose and Cardiovascular Health Require Attention

Prostate cancer survivors frequently have diabetes, hypertension, coronary disease, arrhythmias, or heart failure. These conditions do not automatically prevent HBOT, but they influence treatment planning.

Patients with diabetes commonly require glucose testing before treatment. Meal timing, insulin administration, oral medications, and recent glucose trends should be reviewed because hypoglycemic symptoms can be difficult to evaluate inside a pressurized chamber.

Hyperbaric oxygen can increase systemic vascular resistance and reduce heart rate and cardiac output. Patients with unstable or decompensated heart failure should be medically optimized before treatment. New dyspnea, edema, chest pain, or changes in exercise tolerance should be reported promptly.

The goal of screening is not simply to identify whether the patient can enter the chamber. It is to create a treatment plan that accounts for the individual’s broader cardiovascular, pulmonary, metabolic, and oncologic health.

Measuring Whether HBOT Is Working

Visible hematuria is an important outcome, but it is not the only measure of treatment benefit.

Clinical progress may include:

• Fewer bleeding episodes
• Reduced volume of blood or clot passage
• Fewer emergency visits
• Reduced need for irrigation or catheterization
• Stabilization of hemoglobin
• Reduced transfusion or iron-replacement requirements
• Improved urinary frequency or urgency
• Reduced dysuria or bladder discomfort
• Better sleep and daily function
• Reduced need for additional invasive procedures

Patient-reported outcomes are particularly valuable because chronic radiation cystitis can affect several aspects of urinary function simultaneously. A patient may consider treatment worthwhile because urgency improves enough to permit travel or uninterrupted sleep, even when occasional mild hematuria persists.

The Expanded Prostate Cancer Index Composite, or EPIC, has been used in radiation cystitis research to measure urinary symptoms and their effect on quality of life. The RICH-ART trial demonstrated improvement in patient-reported urinary outcomes after HBOT compared with standard care. (AME Medical Journal)

What the Evidence Shows

The evidence supporting HBOT for chronic radiation cystitis includes cohort studies, systematic reviews, and a multicenter randomized phase 2 to 3 trial.

A 2024 systematic review and meta-analysis involving patients with radiation-induced hemorrhagic cystitis found overall symptom improvement in approximately 90 percent of treated patients. Complete remission of hematuria occurred in a pooled 55 percent. The included studies varied in severity, treatment protocol, follow-up, and definitions of success, so these figures should not be presented as a guaranteed individual outcome. (PubMed Central (PMC))

Studies focused specifically on men treated for prostate cancer have reported durable improvement following HBOT, although results vary according to baseline bleeding severity and other clinical factors. One prostate cancer cohort found that the initial grade of hematuria was associated with the likelihood of resolution, information that may be useful during shared decision-making. (PubMed Central (PMC))

The 2025 five-year follow-up of the RICH-ART trial provides important long-term evidence. Among 70 patients included in the follow-up analysis, 48, or 68.6 percent, met the study’s responder definition after HBOT. Symptom improvements remained clinically meaningful over five years in the responder group, although some patients received an additional HBOT course after symptoms recurred. (PubMed)

These findings support HBOT as a durable treatment option for selected patients, but not every patient responds completely. Severe structural bladder damage, continued anticoagulation, recurrent malignancy, extensive ulceration, delayed referral, and other health conditions may affect the outcome.

Risks and Contraindications

HBOT is generally well tolerated when it is delivered in a medically supervised facility, but it has recognized risks.

Potential adverse effects include:

• Middle-ear or sinus barotrauma
• Temporary myopic vision changes
• Claustrophobia or confinement anxiety
• Blood glucose instability
• Pulmonary oxygen effects
• Rare oxygen-induced seizure

An untreated pneumothorax is generally considered an absolute contraindication. Pulmonary air trapping, difficulty equalizing middle-ear pressure, unstable heart failure, seizure risk, implanted medical devices, and medication interactions require individualized assessment.

A history of prostate cancer is not itself a contraindication to HBOT. The treatment is directed at radiation-damaged tissue rather than the malignancy. Appropriate cancer surveillance should still continue before, during, and after the hyperbaric treatment course.

The Practical and Emotional Burden of Treatment

A full HBOT course may require daily attendance for six to eight weeks. Patients may also be managing urology appointments, PSA testing, catheter care, incontinence, anemia, cardiovascular disease, or other long-term effects of prostate cancer treatment.

Transportation, employment, caregiving responsibilities, urinary urgency, mobility limitations, and treatment fatigue should be discussed before the course begins.

The psychological burden of hematuria is also significant. Blood or clots in the urine can cause fear that prostate cancer has returned, even after testing supports radiation injury as the diagnosis. Recurrent bleeding may make patients reluctant to travel, exercise, participate in sexual activity, or spend time away from immediate restroom access.

Clinicians should explain clearly that HBOT is neither an instant method of stopping hemorrhage nor a guaranteed cure. It is a tissue-restorative treatment intended to improve the bladder’s vascular and healing environment over time.

For appropriately selected prostate cancer survivors, HBOT may reduce bleeding, improve urinary symptoms, limit repeated procedures, and support preservation of bladder function. The strongest care pathway combines hyperbaric treatment with continued urologic evaluation, prostate cancer surveillance, medication management, and prompt treatment of any acute bleeding complication.